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Abstract: The objective of this work was to develop two different materials; lanthanide-
doped CaSO4 (CSO) and Cu@Au gold nanoparticles (GNPs) for particle temperature 
sensing and biomedical applications, respectively.  
In the first part, we synthesized CaSO4 with different lanthanides and characterized the 
resultant samples using x-ray diffraction (XRD), radioluminescence (RL), and 
thermoluminescence (TL). The TL emission was observed in most trivalent states of 
lanthanides including Ce3+, Pr3+, Sm3+, Gd3+, Tb3+, Dy3+ and Tm3+. In case of Eu-doped 
samples, both Eu2+ and Eu3+ emissions were observed. In addition, we observed a variety 
of TL peaks with emission from < 100 C to ~ 600 C with different intensities. For 
temperature sensing applications, we were particularly interested in samples doped with 
Ce and co-doped with either Pr, Gd or Tb, due to their TL emission in the UV region with 
higher intensity than the single-doped samples as well as the existence of TL peaks in the 
high temperature region. The results validates that the appropriate choice of dopants can 
produce TL peaks distributed over a wide range of temperature with high TL intensity. For 
temperature sensing applications, materials with TL peaks in specific temperature regions 
are required, therefore, CaSO4 doped with different lanthanides are good candidates for 
such a purpose. Moreover, we investigated the feasibility of various methods such as initial 
rise method and various heating rate method to characterize the kinetics of the TL in CSO, 
including the determination of the order of kinetics, the activation energy (E) and the 
frequency factor (s). 
In the second part, we developed and characterized Cu@Au GNPs using TEM, TEM/EDS, 
UV-vis, XPS and ICP. The binding properties of the GNPs were then evaluated in human 
lung cancer cells. Animal studies were implemented by doping radioactive hybrid GNPs 
with 64Cu (t1/2= 12.7 h). For that purpose, the 
64Cu@Au GNPs were injected into animals 
for studying their biodistribution and pharmacokinetics. Since our hybrid Cu@Au GNPs 
(in which the shells are gold) have identical outer structures to that of regular GNPs, the 
existing GNP targeting and nano-carrier methodologies can be employed. This allows an 
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This dissertation provides an overview of two major projects, describes the results obtained so far 
and gives the suggestions for future work.  The first part of this dissertation (chapters 2-6) concerns 
the development of lanthanides-doped calcium sulfate (CaSO4) for temperature sensing 
applications using the Thermoluminescence (TL) technique. The second part of the dissertation 
(chapters 7- 11) concerns the development of specific gold nanoparticles (GNPs) for targeting lung 
cancer cells along with some physical and biological studies on these particles. 
Hypotheses 
Since the rationale of my Ph.D. research is to improve two types of materials for two different 
applications, the hypotheses consist of two parts. The two hypotheses are as follows: 
 The TL properties of potential materials for temperature sensing can be tuned to this 
application by modification of the dopants. This hypothesis is tested on CaSO4 doped 
and/or co-doped with lanthanide ions. 
 Cu@Au nanoparticles doped with a positron emitting radionuclide exhibit same physical 
(light absorption, radiosensitization, etc.) and biological (biodistribution, clearance, 
toxicity, etc.) properties as that of similar sized traditional GNPs. 
Specific Aims 
The following aims were made to verify the hypotheses. Aims 1-4 focus on the first hypothesis and 




Vary the amount of sulfuric acid used as the sulfate precursor in calcium sulfate (CSO) structure to 
investigate what amount results in maximal TL intensity and desirable TL peak temperatures.  
Aim 2 
 Dope CSO with different lanthanides of interest for luminescence. Singly-doped CSO will be 
synthesized with all lanthanides (except La, Pm, and Lu) and will be characterized using x-ray 
diffraction, radioluminescence (RL), TL emission spectra, and TL glow curves using both broad-
band detection and wavelength-resolved detection. We will focus particularly on samples 
containing blue and UV emitting centers (e.g. Ce3+, Gd3+, Tm3+) because of the better discrimination 
between TL emission and blackbody background emission.   
Aim 3 
Co-doping CSO with lanthanides to investigate the effect of co-dopants to introduce TL peaks at 
even higher temperatures. CSO will be co-doped with Ce because this leads to UV emission and a 
TL peak in the high-temperature range (~500 C), combined other co-dopants (Pr, Gd, Tb, and Tm) 
to obtain as many TL peaks as possible over a broad range of temperatures. 
Aim 4 
Co-doping lanthanides with alkali metals to investigate if specific alkali metals could be used to 
introduce additional trapping centers in CSO and extend the temperature range of applicability of 
this material. Co-dopants (Li, Na, K) will be investigated. 
Aim 5 
Developing non-radioactive copper-gold nanoparticles (Cu-GNPs) following by doping their core 
with positron emitting radionuclide 64Cu. The synthesized GNPs will be characterized using a 




Testing GNPs in vitro (human lung cancer cells) for targeting capability and cytotoxicity. For this 
Aim, we will target the 64Cu-GNPs to a specific cell line and trace them using a gamma counter.  
Aim 7 
We will apply the radioactive the 64Cu-GNPs in vivo and determine the pharmacokinetics of the 
64Cu-GNPs. As a logical extension of the pharmacokinetic study described above, we will study 
what organ/organ systems are responsible for clearance of GNPs from the blood. 
The remainder of this thesis is divided into 11 chapters. Beginning with part one, chapter 3 presents 
the background information required to understand the TL mechanism. Chapter 4 presents the 
methodology used for specific Aims 1-4. Each section of chapter 5 and 6 focuses on one specific 
objective that is required to complete the improvement of CSO for temperature sensing and 
discusses the results. Chapter 7 concludes the research of each specific Aims 1-4, and suggests 
possible future studies. Continuing to part two, chapter 8 introduces some background on Gold 
Nanoparticles (GNP). Chapter 9 describes the basic methodology and characterization techniques 
used for GNP studies. Chapter 10 presents the research for Specific Aims 5-7 and discusses the 
results. Chapter 11 summarizes and concludes the research of each specific Aims 5-7, and suggests 





















The first part of this dissertation focuses on the Thermoluminescence (TL) technique and its 
application in temperature sensing. The TL technique is broadly used for personnel and 
environment radiation dosimetry, archaeological and geological dating, and defect investigations 
of solid samples [1]. This technique has also been recommended for temperature measurements of 
fire damage in concrete [2], to provide the thermal history of meteorites [3-5], and to investigate 
firing temperatures in ceramics [6]. 
Another application of TL is for temperature measurements in the environment of a detonation. 
When an explosion happens in any environment, we need to know the temperature of the core of 
explosion in order to assess the effects such temperatures may have on biological organisms. 
Measuring such high temperature in the event of explosion cannot be done by direct measurements 
(e.g. thermometer) and new techniques are needed. The lack of particle sensors that can track the 
temperatures encountered by flowing particles exposed to a detonation event has raised the 
motivation to investigate the development of particles for temperature measurements [7-12]. The 
basic idea for TL materials acting as passive temperature sensors is the fact that the temperatures 
to which the particles are exposed affect the trapped charges at different energy levels to different 
extents depending on the characteristic trapping parameters, namely the activation energy of the 
trapping center E and frequency factor s [1]. In principle, therefore, the subsequent TL curve of an 
irradiated material can be used to discover not just the irradiation dose, but also the thermal history 
of the sample since irradiation. Therefore, the temperature to which the particles are exposed can 
be extracted by comparing the TL curves of those particles the experienced a temperature profile 
6 
 
to the TL curve of control particles [13-16]. Required material properties for temperature-sensing 
applications include high TL intensity, low light sensitivity (bleaching), low dark-storage fading, 
and multiple TL peaks particularly in the high-temperature range of the TL curves. The research 
group at OSU has worked for several years on this problem and developed some materials suitable 
for temperature sensing, including lithium borate (Li2B4O7), magnesium borate (MgB4O7) and 
calcium sulfate (CaSO4) [13, 16, 17]. These materials have been tested for temperature 
measurements in the laboratory and in detonation chambers [16, 18]. Previous work on calcium 
sulfate (CSO) from our group has shown that this material has multiple stable TL peaks at 
temperatures between 100 oC- 430 oC [13]. The peaks show low dark fading and insignificant 
sensitivity to light. CSO:Ce0.2%,Tb0.2% has been used for temperature measurements tests with the 
main TL peak at 325 oC which is due to Ce3+ emission. Since Ce emission is in the UV range and 
the blackbody radiation is in the red region, we can minimize the overlap of the blackbody radiation 
by monitoring the emission from Ce3+ hence the two are easily separated. The sensitivity (i.e. 
TL/dose) of CSO:Ce0.2%,Tb0.2% has been shown to be twice that of LiF:Mg,Ti (a commercial TL 
material) and its signal intensity can be increased by increasing the irradiation dose as our dose 
response data confirmed. The step annealing data for CSO:Ce,Tb indicate that the kinetics order 
for most of the peaks is close to one [13].  
Due to the properties identified above, CSO is a material of interest for further improvement. There 
exists the possibility of extending its TL peaks toward higher temperature by changing the choice 
of dopants and their concentrations. A systematic study is needed to be done on the role of co-
dopants and the dopant concentration on the TL properties of this material. Furthermore, the lack 
of a detailed model for the trapping and recombination processes in CSO hinders further material 
development. By investigating a model that can describe the TL mechanism in CSO, the goal is to 









Basis description of the TL phenomenon 
Thermoluminescence (TL), also known as Thermally Stimulated Luminescence (TSL), is a 
technique that measures the emission of light as a function of temperature while heating insulators 
and semiconductors that were previously exposed to ionizing radiation [1]. In a typical TL process, 
a sample is exposed to (irradiated by) ionizing radiation (e.g., beta rays); then it is gradually heated 
and the light emission is recorded. The emission is due to the thermally stimulated recombination 
of electrons and holes trapped in defects in the crystalline lattice, and it results in a so-called “TL 
glow curve”, normally consisting of one or more peaks corresponding to the release of electrons 
and holes from different defects within the lattice.  As an example, the TL glow curve of CSO:Tm 
and CSO:Dy is shown in Figure 1. What distinguishes blackbody radiation from TL is the fact that 
blackbody radiation is an emission from an object due to the temperature of that object but the light 





Figure 1. TL glow curve of CaSO4:Tm and CaSO4:Dy [19] 
 
We can use band gap model to explain the TL mechanism. The outer electrons of an atom that are 
involved in the chemical bonding exist in valence band whereas the conduction band consist of free 
electrons. In semiconductors and insulators such as materials that we develop for temperature 
sensing, there exists a gap between these two bands that is empty of electrons. The band gap is the 
energy needed to exite an electron from the upper state of the valence band to the lowest state of 
the conduction band (Eg= Ec- Ev). The movement of electron from valence band to the conduction 
band leaves behind a hole in valence band. In a perfect semiconductor, there are no charge carriers 
in the bandgap and electrons and holes only exist in the delocalized bands (valence and conduction 
bands) but we can introduce defects into the crystalline lattice to create additional states within the 
bandgap. These states are called localized bands or levels and behave as either charge traps or 
recombination centers.  
 The simplest model for TL studied by Garlick and Wilkins, Garlick and Gibson, and Randall and 
Wilkins (1945 a, b; 1948) consists of only two localized levels (i.e. a trap and a recombination 
center) within the energy band as shown in figure 2. When the material is irradiated with the energy 
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greater than the band gap energy, free electrons and free holes will be produced in the conduction 
band and in valence bands, respectively (process 1). The charge carriers then have 3 options: (a) 
recombine with each other; for this to happen, holes need to get trapped in recombination centers 
(R) (process 5), and then recombine with electrons (process 4). This recombination will result in 
luminescence if the transition is radiative. (b) Free electrons at first get trapped at trapping centers 
(T) (process 2) and then gain enough energy (thermal energy in our case) to go back to conducting 
band (process 3) and from there recombines with holes at recombination centers. The type of 
luminescence observed depends on the time between the irradiation and recombination as well as 
the temperature to which the sample is exposed. Recombination with < 10-8 - 10-3 s after excitations 
with the minimum effect of temperature is called fluorescence, while phosphorescence occurs by 
longer timing between excitation and recombination, and are highly affected by temperature. 
Thermoluminescence is listed under the phosphorescence process. 
For the process explained in (b), the probability for an electron being released from the trap per 
unit time (𝑝) is defined by the Arrhenius equation 3.1 [1].  
        




                                                                                                               
Where 𝜏 is the mean time spent in a trap, 𝑠 is a constant, 𝐸 is the trap depth, 𝑘 is Boltzmann’s 
constant and 𝑇 is the temperature. 
According to Randall & Wilkins (1945a, b), if the probability of retrapping is negligible comparing 
to the probability of recombination, the TL model results in first-order kinetics. On the other hand, 
if the probability of retrapping is significantly greater than the probability of recombination, the TL 
peak is said to have second-order kinetics. If the probabilities are somewhere between these two 
limits, the TL will yield to general-order kinetics as suggested by May and Partridge [20] and 













Order of Kinetics 
As mentioned before, all luminescence processes happen due to the change in the population of the 
charge carriers in the localized bands. For the simple one trap one recombination model explained 
in the previous section (see Figure 2), a mathematical model can be shaped by knowing the rate 
equations governing the population of the electrons and holes in the electron trap/ the conduction 
band and recombination center/ valence band respectively. These rate equations are written as the 
following [1]. 
1) The rate of change in the concentration (number per unit volume) of trapped electrons: 
                      −𝒅𝒏 𝒅𝒕⁄ =  𝒏𝒑 − 𝒏𝒄(𝑵 − 𝒏)𝑨𝒏 (0.2) 
  
where n is the concentration of trapped electrons, p is the probability for an electron being released 
from the trap per unit time (see eq. 3.1), nc is the concentration of electrons in conduction band, N 
is the concentration of electron traps, and An is the probability of electrons trapping at electron 
traps. 














Figure 2. Simple model for Thermoluminescence (after 
McKeever, 1985)  [1] 
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𝒅𝒏𝒄
𝒅𝒕⁄ =  𝒏𝒑 − 𝒏𝒄(𝑵 − 𝒏)𝑨𝒏 −  𝒎𝒏𝒄𝑨𝒓 (0.3) 
where m is the concentration of holes at the recombination center, and Ar is the probability of 
electrons and holes recombination at a recombination center. 
3) The rate of change in the concentration of holes at the recombination center: 
                      𝒅𝒎 𝒅𝒕⁄ = −𝒎𝒗(𝑴 − 𝒎)𝑨𝒎 −  𝒎𝒏𝒄𝑨𝒓 (0.4) 
 
where mv is the concentration of holes in valence band, and M is the concentration of recombination 
centers and Am is the probability of  holes being trapped at a recombination center. 
4) The rate of change in the concentration of holes in valence band: 
                      
𝒅𝒎𝒗
𝒅𝒕⁄ = 𝒎𝒗(𝑴 − 𝒎)𝑨𝒎 (0.5) 
 
For this simple model, the charge neutrality assumption dictates that the sum of electrons in 
conduction band and trapped electrons should equal the total concentration of holes in the valence 
band and trapped holes, i.e. 𝑛𝑐+ 𝑛 =  𝑚𝑣 + 𝑚. An important assumption to simplify the rate 
equations is called the quasi-equilibrium (QE) condition that means the population of electrons in 
the conduction band and the rate of change in their population in conduction band is much smaller 
of that of the trapped ones, that is 𝑛𝑐 ≪ 𝑛 as well as |𝑑𝑛𝑐/𝑑𝑡| ≪ |
𝑑𝑛
𝑑𝑡
| [21].  
With these assumptions, the TL intensity (I) is equal to the rate of reduction in the concentration of 
the trapped electrons or holes by time. 
                      𝑰(𝒕) =  −𝒅𝒏 𝒅𝒕⁄ ≅ −𝒅𝒎/𝒅𝒕 (0.6) 
 
Combing this equation with the rate equations (3.3, 3.4, 3.5), the TL intensity can be written as the 
following [22]: 






     (0.7) 
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Equation 3.6 is General On-Trap (GOT) equation for a TL curve that only consists of one single 
peak. However, in reality, a material can show multiple TL peaks. Therefore, we need an equation 
that can show the TL intensity as the function of temperature. By applying some simple 
assumptions, we can reach to the equations for first- and second- order kinetics. 
 If we assume that the probability of retrapping is less than the probability of recombination 
((𝑁 − 𝑛)𝐴𝑛 ≪ 𝑚𝐴𝑟), equation 3.6 will be simplified to  
                  𝑰 =  𝒏𝒔 ∗ 𝒆𝒙𝒑(−
𝑬
𝒌𝑻
)     (0.8) 
 
Solving equation 3.7 for n, changing the variable from time to temperature and integrating over 
temperature (assuming 𝑇(𝑡) = 𝑇0 + 𝛽𝑡 ;  𝛽 = 𝑑𝑇/𝑑𝑡) generate the TL first-order equation (eq. 3.8) 
proposed initially by Randall and Wilkins (RW TL equation) [23, 24]. 












     (0.9) 
 
On the other hand, if we assume that the probability of retrapping is more than the probability of 
recombination ((𝑁 − 𝑛)𝐴𝑛 ≫ 𝑚𝐴𝑟), equation 3.6 will be simplified to  






     (0.10) 
 
This equation was solved similarly by Garlick and Gibson to give an expression for TL second-
order peak (GG TL equation).  




𝒔 ∗ 𝒆𝒙𝒑 (−
𝑬
𝒌𝑻











     (0.11) 
  
If we change the initial population (n0), the TL first-order peak changes only the height and not the 
position whereas the TL second-order peak changes in both height and position, with the peak 
shifting to higher temperature peak as the initial population decreases. Figure 3 shows a 
computational TL glow peak for both first-order and second-order kinetics. As it can be clearly 
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seen, in the second-order peak, the peaks become broader and shift to higher temperature as n0 
decreases [1]. 
 
          
Figure 3. a) first-order TL peak and b) second-order TL peak computed with several initial 
population, E= 1.0 eV, s=1010 s-1, β=10 C/min (after McKeever, 1985) 
TL in temperature sensing 
Concept 
The concept behind the use of TL for temperature sensing is the following [16]: Particles of a TL 
material are irradiated in the laboratory with a known dose and are then exposed to a thermal event, 
such as an explosion. Such an event causes a rapid change in temperature. The materials are then 
recovered and the residual TL is measured.  We compare the TL glow curve of the control sample 
(the sample that is irradiated with the same dose as the TL material but has not been exposed to a 
thermal event) to that of the recovered experimental samples as shown in Figure 4. The changes in 
the TL glow curve are due to the temperature to which the sample was heated, and the time for 
which it was at that temperature. If the time is known or estimated, then the temperature to which 




Figure 4. The TL curve for CSO:Ce,Tb heated in a temperature chamber to 380 oC for 1 s, the 
sample was prepared with 10 Gy  [16] 
Material requirements 
Based on the concept above, an ideal TL material for temperature sensing applications should have 
in practice: 
a) multiple TL peaks, so that we can measure the information over the wide range of 
temperature; 
b)  high sensitivity to radiation, to guarantee that the TL signals are detectable even if only a 
few grains of material are recovered after the detonation (e.g., 106 counts/s for much less 
than 1 mg of material being irradiated with 500 Gy); 
c) high melting point and chemically inert so that the material can survive a high-temperature 
event such as explosions and harsh environments;  
d) low dark fading, to avoid changes in the TL signal until the readout stage in the laboratory; 
since the information of the temperature event is obtained from the TL curve, we desire a 
material for which the TL curve is stable to preserve the information;  
e) insensitivity of the TL signal to light, because sometimes the materials may be exposed to 
light during the detonation, preparation and sample recovery;  
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f) small particle size to mimic the size of biological agents (1-20 microns) and to allow a fast 
response to temperature in a similar way to the bio-agent [13]. 
TL materials used for temperature sensing 
Early studies and commercial materials 
The TL materials that are used for temperature sensing application require different properties than 
those used for dosimetry applications [13]. For temperature sensing, we are more interested in 
materials with high sensitivity to ionizing radiation, insensitivity to light, low dark fading, simple 
TL kinetics and multiple TL peaks that cover the wide range of temperatures, especially toward 
higher temperatures. For dosimetry applications, tissue equivalency and simple TL curves with 
single dominant peaks are of more interest. 
Overview of materials developed at OSU 
Previously, the OSU group has developed several materials for temperature sensing applications,  
including lithium borate doped with copper and silver (Li2B4O7:Cu,Ag), magnesium borate doped 
with lithium and dysprosium (MgB4O7:Li,Dy), and calcium sulfate doped with cerium and terbium 
(CaSO4:Ce,Tb) [13]. These materials have been synthesized in the laboratory using the solution 
combustion method and identified to have important characteristics for temperature sensing, such 
as bright TL emission, low fading, and low bleaching at room temperature. The TL intensity of 
these materials is comparable to the TL intensity of the commercial TL material,  LiF:Mg,Ti,  at 
low doses but with the added advantage of saturating at higher doses (e.g. at 500 Gy, the signal for 
CSO is still increasing while it is already saturated for LiF:Mg,Ti) [13]. Moreover, the TL for these 
materials is close to first-order kinetics. These materials have undergone detonation tests at the 




Calcium sulfate as a TL temperature sensors 
Early studies and dosimetric properties 
CaSO4 (CSO) is a TL material of interest for this project because not only does it fulfill the material 
requirements but it can extend the temperature range of measurement towards higher temperatures 
due to the presence of bright, high-temperature TL peaks and UV emission [25]. 
CSO is used as a host material in different technology areas. Single-phased, undoped CSO is used 
as a wide-optical-bandgap host for white light phosphors because of its excellent chemical and 
environmental stability. CSO:Eu is a candidate for photoluminescent liquid crystal displays 
(PLLCD) and radio-photoluminescence dosimetry, and CSO:Eu,Sm serves as optical storage 
material [26-28] 
The thermoluminescence of CSO, particularly doped with rare earth elements (RE) (e.g., 
CaSO4:Dy, CaSO4:Tm), has been of interest for dosimetry applications since as early as 1955 [29-
32]. They can have sensitivities 30 or 60 times higher than LiF:Mg,Ti (CaSO4:Dy and CaSO4:Tm 
respectively) [25], are unaffected by heat treatments below 700 C, and can be economically 
synthesized in the laboratory [33]. CSO:Dy, CSO:Tm and CSO:Sm are used in environmental 
radiation measurements and personnel monitoring [19, 32]. 
CSO has a high melting point (1460 C) and can be synthesized by several methods, such as the 
recrystallization technique [19], solid state metathesis [32] and precipitation or acid distillation 
[28], usually followed by a heat treatment. The synthesis method for commercial CSO used in 
dosimetry is either single crystal growth or polycrystalline growth as described first by Yamashita 
et al [19]. 
Defects and TL properties 
TL properties of CSO have been investigated over the years. Several emissions from lanthanide 
dopants such as Tm3+, Dy3+, Eu2+,Eu3+, Ce3+ and from metals such as Mn2+, Cd2+, Zn2+, and Pb2+  
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were reported [29, 34-36]. Also, the main TL glow peaks and the effect of RE impurities on the TL 
properties of CSO have been studied by Nambi et al. [33]. Over the years, there has been some 
models proposed to better understand the TL process in CSO:RE (rare earth). Two main models 
are the following: 
a) The ‘redox reaction’ model proposed originally by Nambi et al. [33] and later supported 
by Calvert, Danby and Dhopte (1984, 1991a). In this model, the TL process in CSO is 
described as follows: when CaSO4 is doped with a rare earth (RE), the RE3+ ion replaces 
Ca2+ in the lattice. During the irradiation stage, the RE3+ ion is reduced to RE2+ (electron 
capture) resulting in a hole trapped in the lattice (for example at SO3- or O3- radicals). 
During heating, the hole releases from the lattice, recombines with the trapped electron at 
RE2+ site, and the RE2+ ion is oxidized to an excited state of RE3+. The subsequent decay 
of excited RE3+ to its ground state will result in the TL emissions characteristic of the RE3+ 
ion.  Figure 5 shows the band diagram for this model.  
 
Irradiation: 
                            RE3+ + e-  RE2+ 
                            h+ + SO3- (O3-)  SO3 (O3) 
 
readout:                             SO3 (O3)  SO3
- (O3-) + h+ 









The nature of trapping centers and their energy depth highly depend on the RE energy 
levels relative to the valence and conduction bands [37]. This model fails to explain the 
emissions from several lanthanides such as Ce3+, since in these lanthanides the RE2+ energy 
levels are very close to or located in the conduction band, so the electrons can easily escape 
to the conduction band. Some other lanthanides such as Pr, the trap depth is too small, 
therefore, the trapped electrons are not stable in the room temperature [38]. 
b) The ‘recombination/energy transfer’ model proposed by Nambi et al [33] and supported by 
other researchers [35, 39, 40]: Here, the choice of dopant does not affect the basic trapping 
and recombination processes. According to this model, during the irradiation stage, 
electron and hole traps are produced. The hole traps (“radicals” such as SO3-, O3-) produce 
stable trapping sites with varying activation energies that results in the multipeak TL glow 
curves. In undoped CSO, these trapping sites may not be produced with high efficiency or 
they may recombine shortly after production. During the readout stage, the electrons and 
holes recombine producing energy. This energy is then transferred to RE dopant resulting 
in the characteristic emission of RE.  Figure 6 depicts the band diagram of energy transfer 
model. 







Figure 6. Band diagram depicting Stoebe’s energy transfer model for TL process in CSO:RE 
 
According to this model, TL peaks should always occur at the same temperatures since the trapping 
centers are the intrinsic centers inside the CSO lattice regardless of the choice of dopants.  However, 
this model does not identify the recombination centers. In addition, the details of such an efficient 
energy transfer that can be applicable within the distance of recombination sites and lanthanide 
defects are still unknown. 
Previous development at OSU 
CSO was previously doped with 0.2% of Ce and Tb in the OSU laboratory and the samples were 
characterized by XRD, SEM and TL techniques. The crystalline structure of CSO was confirmed 
by XRD  and, by using the micrographs from SEM, it was shown that grain size of less than 20-30 
µm can be obtained [13]. The main TL peak from CSO:Ce,Tb was reported at 350 oC, and the TL 
emissions at ~ 306 and 324 nm were reported to correspond to Ce3+ emission. Other emissions were 
attributed to Tb3+. The TL kinetics was shown to be close to one. 
There is at present very little information on CSO regarding the nature of trapping and 
recombination centers. There has been no systematic study to show the temperature of occurrence 
and wavelength of the lanthanide TL emissions simultaneously (TL emission spectra are reported 
only for a few lanthanides). Also, there has been very little reported on the role of co-doping 
lanthanides with other lanthanides or other elements (such as alkali metals). The effect of co-doping 
on the TL properties of CSO has not been yet reported in a systematic way. Also, the effect of 
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varying the dopant concentrations and energy-transfer phenomenon in CSO has been studied only 
for few lanthanides.  
TL analysis techniques 
In order to understand the behavior of TL curves, we need to have insight into the kinetic order of 
the TL peaks and the characteristic trapping parameters including the trap depth, E, the frequency 
factor, s, and the densities of traps and recombination centers. Although calculating these 
parameters does not imply a full understanding of the defect models, it is still the first step to 
understand the behavior of the TL glow curve during irradiation and heating and choose the 
appropriate rate equation governing the process in order to develop the suitable TL materials.  The 
real TL materials developed in the lab typically have multiple TL peaks and for the better fitting of 
a TL glow curve into a set of peaks, linear superposition is assumed. The linear superposition can 
be used for curve fitting only if the peaks have first-order kinetics [41]. For the higher-order 
kinetics, however, since the traps are not independent, the curve fitting with superposition 
assumption is flawed. Therefore, it is important to recognize the order of kinetics for each TL peak 
of the developed material. The analysis of the TL data is usually divided into two groups, trap 
emptying (such as initial rise, peak shape, and peak position methods) and trap filling (dose-
response) and both parts together can give us a good estimation of the order of kinetics. In this 
section, multiple methods to determine the kinetic order of the trapping centers are introduced.  
Dose Response 
The dose-response curve is a property to investigate the behavior of TL curves as the trapping 
centers are being filled. If the sample is irradiated to different doses, and the TL intensity versus 
dose is plotted, and if the position of maximum TL peak is not shifted as the traps are being filled, 
this might be due to the first-order kinetics. To confirm, we need also to look at the order of kinetics 
of the TL peak as the traps are being emptied. 
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Initial rise method 
The Initial Rise Method (IRM) first introduced by Garlick & Gibson (1948). In this method, the 
initial part of a TL curve is assumed to be dependent on temperature according to the following 
equation and that the heating temperature is low enough to keep the trap occupancy (n) 
approximately constant in the initial part of the curve [1]. If we assume that n is approximately 
constant in any of the equations 3.8, 3.9, and 3.11 we can write: 




where C is a constant. If we plot ln (I) versus 1/kT over the initial region, the slope of the line will 
be –E allowing us to determine the activation energy, E. Figure 7 shows the schematic 
representation of the regions use in IRM. 
 
Figure 7. Schematic representation of the initial region in IRM  
 






 becomes zero 
and RW equation (equation 3.9) will simplify to equation 3.14. If the initial rise rise region behaves 
like a first-order kinetics and is well isolated, the frequency factor, s, is calculated by equating the 












where β is the heating rate (K/s), and K is the Boltzmann constant. The limitation that challenges 
this method is that n remains approximately constant. This requirement becomes invalid while a 
temperature exceeds a critical value, Tc. Kivits & Hagebeuk (1977) demonstrated that the 
corresponding intensity of the initial part of the curve should not exceed the 10-15% of the 
maximum intensity [42]. 
Another limitation for this technique is that it can be only applied when the glow peaks are well 
separated from each other and well defined. To overcome this limitation and to make sure that the 
TL peak of interest is not made of multiple, overlapping TL peaks, we employ another method 
called “step annealing” [42].  
Step Annealing 
This approach is a modified “Thermal Cleaning” method that was attempted before by Nicholas & 
Woods (1964). The TL curves often consist of multiple overlapping peaks. To ensure the cleaning 
of the initial rise of the curve from the low-temperature peaks and isolate the region from the high-
temperature peaks, the material is preheated to a given temperature Tstop after being irradiated and 
then, the entire TL curve is recorded from room temperature up to the peak temperature, Tm. The 
pre-heating temperature, Tstop, is raised with steps of 2 - 5 oC. This method yields to sequential 
depletion of low TL curves and helps to isolate the initial rise part of the higher TL temperature 
peaks. The outcome is called aTm- Tstop  plot and contains useful information regarding the order of 
kinetics (see Figure 8). The following figure compares the first and second-order TL peaks in both 
TL plot and a Tm- Tstop plot. The limitation that Tm- Tstop plot has is that smaller peaks (low-intensity 
peaks) can remain hidden by their more prominent neighbors. The accuracy of this method is only 




Figure 8. Line A: TL glow curves. Line B: Tm-Tstop plot for first-order. Line C: Tm-Tstop for second-
order. Coloum a: single glow peak. Coloumn b: overlapping peaks. Coloumn C: quasi-continuous 
distribution of peaks (after McKeever, 1985). 
Various heating rate method 
The trap depth can also be calculated based on the positions of the maximum of TL peak (Tm).  In 
Various Heating Rate Method (VHRM), E can be calculated from the change in Tm caused by 
altering the heating rate (β) during TL measurement [42]. During the TL process, heating is 
generally stays as a linear function, T(t) = T0 + βt ;  β = dT/dt. When the heating rate is 
increased, and all other parameters are kept the same, the TL peak will be shifted to higher 
temperatures, the maximum intensity will be decreased, and the width will be increased in order to 
maitntain a constant total area under the peak as seen in Figure 9. 
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Figure 9. First-order glow curves of CSO:Eu for VHRM  
 
 By differentiating the RW equation for first-order peak (eq 3.9) with respect to temperature and 
equating the derivative to zero at T=Tm , the following equation for β can be derived. 
)/exp()/( 2 mm kTEEskT   (0.16) 
For the experimental cases, when several heating rates are employed, Hoogenstraaten (1958) 
suggested noting the value of Tm for each corresponding heating rate and then plotting )/ln(
2 mT
versus 1/KTm. E can be calculated from the slope and s from the y-intercept (Ln(E/sK)) of a linear 
fit of such a graph.  So far, VHRM has been applied to first-order TL peaks but has been shown to 
be a good approximation for non-first-order kinetic TL processes as suggested by Chen & Winer 
(1970).  
The merit of this method is that the only data needed are Tm and Im which leads to a fast and simple 
data collection. However, this method is mostly reliable for the most prominent peaks and can be 
flawed at higher heating rates. Also, this method fails to determine the activation energy for closely 
overlapping peaks due to closely grouped trapping centers since it tracks the position of a singular 
peak and not that of the individual peaks within the distribution. 
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Objectives of this study 
Given the limitations described in previous sections and the lack of ideal TL materials for 
temperature sensing, particularly in the high temperature range, the objective of this work is to 
investigate approaches to improve the thermoluminescence (TL) properties of CaSO4 (CSO) for 
particle temperature sensing applications by controlling the TL properties of CSO and extending 
its applicability to higher temperatures. 
To achieve this, we carried out a systematic investigation of the luminescence properties of CSO 









MATERIALS AND METHODS 
Synthesis and sample preparation 
In this study, instead of crystal growth, the co-precipitation method was used for material 
preparation. This synthesis method is simple and allows the rapid production of samples doped 
with different lanthanides in powder form suitable for temperature sensing applications [13].  
CaSO4:Ln samples were synthesized by co-precipitation, using the method described by 
Lakshmanan [34]. CaCO3 and the needed concentration of dopants (see Table 1) were dissolved in 
deionized water. The solution was stirred at room temperature for 20 min. Sulfuric acid was diluted 
separately and poured into the CaCO3 solution gradually using a separatory funnel while stirring 
the solution with a stirring magnet. The solution was then dried on the hot plate at 170 oC. Once 
the solution water was evaporated, the hot plate temperature was raised to 360 oC allowing the 
unreacted sulfuric acid to completely evaporate. The material was annealed in an alumina crucible 
in a box furnace at 700 oC for 2 h. The resultant powder was then crushed and ready for the 
characterization [38]. The grain size obtained was less than 15 micrometer as will be explained 
more in the following sections. The samples that were used in this study are summarized in Table 








Table 1. Samples used in this study with the order of Lanthanides 
Batch Label Batch Date Description Dopant 
SB131119-2 Nov. 2013 CaSO4:Ce0.2% Ce(NO3)36H2O, REacton®, 
99.5% 
SB131110-1 Nov. 2013 CaSO4:Pr0.2% Pr(NO3)3xH2O, 99.9% 
SB131030-2 Oct. 2013 CaSO4:Nd0.2% Nd(NO3)36H2O, 99.9% 
SB131106-2 Nov. 2013 CaSO4:Sm0.2% Sm(NO3)36H2O, 99.9% 
SB131030-1 Oct. 2013 CaSO4:Eu0.2% Eu(NO3)36H2O, REacton®, 
99.9% 
SB131106-1 Nov. 2013 CaSO4:Gd0.2% Gd(NO3)3xH2O, x6, REacton®, 
99.9% 
SB131126-2 Nov. 2013 CaSO4:Tb0.2% Tb(NO3)3xH2O, 99.9% 
SB131030-3 Oct. 2013 CaSO4:Dy0.2% Dy(NO3)35H2O, 99.9% 
SB131107-2 Nov. 2013 CaSO4:Ho0.2% Ho(NO3)35H2O, 99.9% 
SB131112-1 Nov. 2013 CaSO4:Er0.2% Er(NO3)35H2O, 99.9% 
SB131126-1 Nov. 2013 CaSO4:Tm0.2% Tm(NO3)3xH2O, x5, 
REacton®, 99.9% 
SB13112-2 Nov. 2013 CaSO4:Yb0.2% Yb(NO3)35H2O, x5 or 6, 99.9% 
SB131107-1 Nov. 2013 CaSO4:undoped  
SB131009 
SB131016 
Oct. 2013 CaSO4:Ce0.2%,Tb0.2%  
SB140610-
8651 
June 2014 CaSO4:Ce0.2%,Tb0.2%<75µm  
SB140703-3 July 2014 CaSO4:Ce0.2%,Pr0.2%  
SB140703-4 July 2014 CaSO4:Ce0.2%,Gd0.2%  
SB140703-1 July 2014 CaSO4:Ce0.2%,Tm0.2%  
SB140703-2 July 2014 CaSO4:Ce0.2%,Tb0.2%, Tm0.2%  
SB140525-1 May 2014 CaSO4:Li0.2% LiNO3, 99.0% 
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SB140525-2 May 2014 CaSO4:Na0.2% NaNO3, 99.0% 
SB140525-3 May 2014 CaSO4:K0.2% KNO3, 99.0% 
SB140602-1 June 2014 CaSO4:Pr0.2%,Li0.2%  
SB140602-2 June 2014 CaSO4:Pr0.2%,Na0.2%  
SB140602-3 June 2014 CaSO4:Pr0.2%,K0.2%  
Particle Sieving 
To identify the size of the particles dry and wet sieving tests were performed.  Since the dry sieving 
did not pass any measurable amount of material, wet sieving was used as an alternative to get the 
desired percentage of the particles <13 µm by mass. TL of the material before and after sieving 
was compared as a way to confirm that the materials’ TL properties were not affected after the wet 
sieving. For the wet sieving, 100 mg of CSO was mixed with 250 mL of ethanol. The mixture was 
sonicated for 45 minutes followed by 10 minutes of stirring to avoid CSO from aggregating in the 
ethanol after the initial sonication. Wet sieving passed 95% of the material. We also collected SEM 
images to verify the size of the particles.  
Material characterization 
X-ray powder diffraction 
We used a powder X-ray diffraction (XRD) to confirm the crystalline structure of the host lattice 
(CSO). A Bruker Advance D8 diffractometer was used in this study and was equipped with an 
LYNXEYE detector (D8-25 ADVANCE Bruker AXS GmbH). The equipment operation voltage 
was 40 kV and the operation current was 40 mA. The diffractograms of the samples were collected 
by placing the samples in PMMA specimen holders and with CuKα radiation filtered by a 0.02 mm 
Ni foil. The scanning specifications are 2 , step size 0.02 degrees, and 0.5 s /step. Crystalline 
structure and phase recognition of the samples were carried out by matching the x-ray 
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diffractograms to patterns from the International Centre for Diffraction Data (ICDD) PDF 2 Release 
2011 Database version 2.1102, PDF card 00-037-1496.  
 
Scanning electron microscopy 
A Quanta 600 field-emission Scanning Electron Microscope (SEM) was used to determine the 
morphology of the samples. The equipment magnification was around 5000 and the acceleration 
voltage was 20 kV. The samples were prepared by two methods: wet and dry preparation. In wet 
preparation, 25 mg of the particles were dispersed in 50 ml of ethanol followed by ultrasonication 
for 15 min. Then, one drop of the suspension was poured on an aluminum stub, allowed to dry and 
coated with gold palladium. In dry preparation, a carbon layer was stuck to the top of a sample 
holder and it became in contact to dry powder so that the carbon layer was coated with only a thin 
layer of CSO. 
Thermoluminescence 
TL glow curves were obtained using a Risø TL/OSL-DA-15 reader with a heating rate of 5 ºC/s in 
nitrogen atmosphere (N2 flow was present usually for 30 s). Typically 10 mg of material placed in 
stainless steel cups was used unless mentioned otherwise. The source of radiation was beta particles 
from 90Sr/90Y (dose rate of 0.1 Gy/s). The TL signal was detected using a photomultiplier tube 
(PMT) together with either U-340 filters (7.5 mm thickness, transmission between 270–380 nm, 
Hoya Corporation, CA, USA) or Schott BG-39 glass filter (6 mm thickness, transmission between 
330-620 nm, Schott AG, Mainz, Germany). To avoid PMT saturation, we used an aperture for 
higher doses, which will be mentioned when relevant. 
Radioluminescence 
Radioluminescence (RL) were measured using an optical fiber system (Ocean Optics USB-2000 
fiber spectrometer, Ocean Optics, Inc., Dunedin, FL, USA). The MagnumTM X-ray (Moxtek Inc.) 
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operated at 40 kV with Ag transmission target. The spectra obtained for this study were not 
corrected for the relative detection efficiency as described by Orante-Barrón, et al. [43].  
 
Photoluminescence 
Photoluminescence emission and excitation spectra were obtained using the Fluorolog-3 
spectrofluorometer (model FL3-22, Horiba Jobin Yvon Inc.) The instrument uses a Xenon lamp 
for excitation and a double grating adjustable monochromators for the selection of excitation and 
emission beams. Light exiting the emission monochromator is collected by a PMT. 
Determination of kinetic parameters 
Dose-response Curves 
A desirable property of a TL material for temperature sensing is a linear relationship between TL 
intensity and the absorbed dose. Dose-response curves were measured for three samples and three 
aliquots of each: CSO:Pr, CSO:Tb and CSO:Tm. The amount of materials used was a few grains 
to avoid the non-uniform distribution of heat to different parts of the cup during the heating stage. 
Samples were irradiated with β radiation for 1,2,5,10,20,50,100,200,500,1000,2000, and 5000s. 
The three aliquots of the same material were normalized to dose. We had to use some apertures for 
bright samples at high doses and the intensities were later corrected for different apertures.  
Step-annealing data 
Step-annealing is a method to determine the dependence of the curve shape on the different preheat 
temperatures and to study if there are more complex peak behaviors (non-first-order kinetics) 
present in our samples. In this method, the material was preheated to a given temperature Tstop after 
being irradiated and then, the entire TL curve was recorded from room temperature up to a 
maximum readout temperature and the temperature of the first TL maximum (Tm) was recorded. 
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The pre-heating temperature was raised with steps of 5 oC. Shift in Tm with Tstop can indicate 
possible non-first-order kinetic for the TL process or the existence of trapping centers closely 
distributed in energy.  
Activation energy by the initial rise method 
As explained earlier, IRM technique was employed after step annealing the samples CSO:Tm, 
CSO:Pr and CSO:Eu to calculate the activation energy. After plotting Ln (I) versus 1/kT, we used 
three approaches to read the slope of the linear fit trend in the initial part of the graph: in the first 
approach, we only used our observation to recognize the initial part of the graph looking for the 
most linear, small section of the graph. This approach is called the “estimate by eye” throughout 
the dissertation. In the second approach, graphs of Ln (I) vs 1/kT are divided into the temperature 
zones in which the initial part of the graphs have fixed temperature range. Then, the slope of linear 
fit in each fixed temperature range is read. We continued the fitting until the graph appears to be 
non-linear in that temperature zone, then we shifted the fitting to a new temperature zone. This 
approach is called “const. temp” in the following chapters. In the third approach, linear fitting was 
employed only to the initial part of the graph in which the temperature does not exceed 10% of the 
correspondent Imax. In chapter 5, the calculated E using different approaches are compared. 
Various Heating Rate Method (VHRM) 
This method was used for 1 mg CSO:Eu0.2% using 6 different heating rates (0.1, 0.2, 0.5, 1, 2, and 
5 o C/s) with a 120 s pause after irradiation of (80 Gy) to let the equilibrium of charge carriers. The 
plot of  ln(𝑇𝑚
2 /𝛽) versus 1/𝑘𝑇𝑚was plotted for all heating rates and the activation energy was 








BASIC LUMINESCENCE PROPERTIES OF CALCIUM SULFATE 
RL of CSO 
The RL spectra for CaSO4 doped with different lanthanides are presented in Figure 10. Except from 
Nd, Ho, Er and Yb-doped samples that did not show significant RL emission, and thus are not 
presented in this document, all other samples show a clear RL emission.  



















































































































































































































































































































































































































































































































































































































































































































Figure 10. RL spectra of CaSO4  doped with different lanthanides. 
 
As seen in the figure above, the most intense emissions belong to samples doped with Sm, Eu, Tb 
and Dy. CSO:Ce shows the typical emission bands of Ce3+ at ~304 nm and 324 nm associated with 
5𝑑 → (2𝐹5 2⁄  , 2𝐹7 2⁄ ). For all other lanthanides, the RL emission bands (or lines) are in a various 
regions of the spectrum (e.g. UV emission for Pr3+ and red to infrared emission for Sm3+). These 
RL emissions are confirmed in the literature and are a good indicator to show that the lanthanides 
have free f shells [38]. The emission bands (or lines) are normalized to the most intense emission 




Table 2. RL emission bands (or lines) identified in CaSO4 doped with different lanthanides. Uncertain 





Emission Emission (cm-1) Relative RL intensity Transition 
Ce 304 nm 32942 cm-1 0.8 % 5d  4f (2F5/2; Ce3+) 
 324 nm 30891 cm-1 0.8 % 5d  4f (2F7/2; Ce3+) 
Pr 230 nm 43447 cm-1 0.2 % 1S0  3H5,6 (Pr3+) 
 251 nm 39773 cm-1 0.4 % 1S0  3F4 (Pr3+) 
 599 nm 16701 cm-1 1.0% 1D2  3H4 (Pr3+) 
Nd     
Sm 561 nm 17829 cm-1 1.0 % 5D2  7F0 (Sm2+) 
4G5/2  6H5/2 (Sm3+) (?) 
 602 nm 16611 cm-1 4.4 % 4G5/2  6H7/2 (Sm3+) (?) 
 627 nm 15952 cm-1 7.8 % 4F3/2  6H5/2 (Sm3+) (?) 
 633 nm 15793 cm-1 8.1 % 5D1  7F0 (Sm2+) 
 687 nm 14548 cm-1 4.3 % 5D0  7F0 (Sm2+) 
 699 nm 14305 cm-1 4.6 % 5D0  7F1 (Sm2+) 
 730 nm 13695 cm-1 4.3 % 5D0  7F2 (Sm2+) 
 766 nm 13050 cm-1 1.1 % 5D0  7F3 (Sm2+) 
 817 nm 12238 cm-1 0.5 % 5D0  7F4 (Sm2+) 
Eu 384 nm 26071 cm-1 100.0 % 5d  4f (Eu2+) 
 591 nm 16919 cm-1 0.5 % 5D0   7F1 (Eu3+) 
 616 nm 16228 cm-1 0.9 % 5D0   7F2 (Eu3+) 
 658 nm 15198 cm-1 0.1 % 5D0   7F3 (Eu3+) 
 694 nm 14419 cm-1 0.4 % 5D0   7F4 (Eu3+) 
 742 nm 13477 cm-1 0.1 % 5D0   7F5 (Eu3+) 
Gd 310 nm 32278 cm-1 2.4 % 6P7/2   8S7/2 (Gd3+) 
Tb 379 nm 26418 cm-1 4.4 % 5D3   7F6 (Tb3+) 
 412 nm 24258 cm-1 4.3 % 5D3   7F5 (Tb3+) 
 434 nm 23026 cm-1 3.1 % 5D3   7F4 (Tb3+) 
 454 nm 22022 cm-1 0.5 % 5D3   7F3 (Tb3+) 
 471 nm 21248 cm-1 0.9 % 5D3   7F2 (Tb3+) 
 487 nm 20516 cm-1 4.7 % 5D4   7F6 (Tb3+) 
 543 nm 18424 cm-1 14.2 % 5D4   7F5 (Tb3+) 
 584 nm 17115 cm-1 2.1 % 5D4   7F4 (Tb3+) 
 620 nm 16141 cm-1 1.2 % 5D4   7F3 (Tb3+) 
Dy 479 nm 20875 cm-1 15.9 % 4F9/2    6H15/2 (Dy3+) 
 571 nm 17521 cm-1 21.4 % 4F9/2   6H13/2 (Dy3+) 
 658 nm 15199 cm-1 0.8 % 4F9/2   6H11/2 (Dy3+) 
 749 nm 13358 cm-1 0.4 % 4F9/2   6H9/2 (Dy3+) 
Ho     
Er     
Tm 345 nm 28966 cm-1 0.9 % 3P0   3H4 (Tm3+) 
 361 nm 27714 cm-1 1.4 % 4D2   3H6 (Tm3+) 
 451 nm 22194 cm-1 3.1 % 4D2   3H4 (Tm3+) 
 474 nm 21076 cm-1 0.7 % 1G4   3H6 (Tm3+) 
 511 nm 19567 cm-1 0.3 % 4D2   3H5 (Tm3+) 
Yb     
undoped 347 nm 28845 cm-1 0.2 %  
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 382 nm 26194 cm-1 0.2 % Eu2+ (?) 
 493 nm 20298 cm-1 0.1 %  
 606 nm 16497 cm-1 0.2 %  
Undoped CSO 
The undoped CSO sample, Figure 11, shows a 3D representation of TL emission spectrum (TL 
intensity versus wavelength and temperature) including a weak TL emission peak at about 100 C 
with several emission bands, the main one at ~495 nm. This emission is due to intrinsic defects or 
contaminants, likely due to trace Mn2+ impurities [44 118]. On the other hand, when the samples 
are doped with lanthanides a variety of luminescence centers are introduced. 
 
Figure 11. TL emission spectrum of undoped CSO (10 C/s, 100 Gy). The weak emissions observed, 
could be due to contaminants. 
 
If we take slices of the TL emission spectrum at 470 𝑛𝑚 < 𝜆𝑎𝑣𝑒 < 500 𝑛𝑚 , and  plot the TL glow 
curve for that range of wavelength, we can compare the TL glow curve of the same sample obtained  






































































Figure 12. a) TL glow curve of undoped CSO, measured by TL Riso reader (5 oC/s, 0.5 Gy, U-340). b) 
TL glow curve of undoped CSO, plotted by choosing the slices of the TL emission spectrum for λave 
between 470- 500 nm (10 oC/s, 100 Gy).  
 
Similarly, if we take the slices of TL emission spectrum (Figure 11) at temperature of 100 oC, and 
plot the emission spectrum (RL), and then compare it with the RL spectrum directly measured , we 
can see that the undoped sample shows only weak RL emission bands that cannot be definitively 
identified as observed in Figure 13 except from the emission at 382 nm which is possibly due to 
Eu contamination. The emissions at 347 nm with a good assumption might be due to traces of Tm and 
the emissions at 493 and 606 nm possibly indicate the traces of Dy. 














































Figure 13. RL spectrum of undoped CSO measured a) directly and b) by choosing the slices of TL 
emission spectrum at T= 100 oC. 
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CSO singly doped with lanthanides 
We investigated CSO doped with different lanthanides of major interest for luminescence (Ce, Pr, 
Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb). The resultant RL, TL, and TL emission spectra were 
characterized.   
As an example of the measurements carried out, Figure 14(a) shows RL emission from CaSO4:Eu, 
indicating Eu2+ emission at 380 nm and weaker Eu3+ emission around ~600 nm. Figure 14(b) shows 
that the main TL peak of this sample is at 180 C, with a higher temperature peak around ~250 C. 
Finally, Figure 14(c) shows the TL peak at 180 C is associated with Eu2+ emission; whereas, the 
secondary peak at 250 C is associated with Eu3+ emission. 
                                (a)                                                                              (b) 
















































































Figure 14. (a) RL spectrum of CaSO4:Eu; (b) TL curve of CaSO4:Eu (5 C/s, 0.5 Gy, BG-39); and (c) 




Figure 15 presents the 3D TL spectra of all CSO:Ln samples synthesized in this study. From these 
results, we can identify total of nine types of luminescence centers participating in the TL process 
of CaSO4, eight of these centers (Ce3+, Pr3+, Sm3+, Eu3+, Gd3+, Tb3+, Dy3+ and Tm3+) show the 
characteristic Ln3+ emission bands (or lines) as identified in Table 2.  In CSO:Eu, both Eu2+ at ~384 
nm and Eu3+  at ~ 591 nm and more are observed as we observed previously from RL spectrum 
(Figure 14a) . The emission bands of Ce are not clearly observed due to low intensity.  
  
                  (a) Ce                         (b) Pr                                (c) Nd 
 
 









                  (j) Er             (k) Tm       (l) Yb 
 
 
Figure 15. TL emission spectra of CaSO4:Ln (10 C/s, 100 Gy) 
 
Furthermore, if we plot the absolute and normalized TL curves for various samples using either 
UV-transmitting filter or visible transmitting filter (see section 0) , there seems to be common TL 
peaks (Figure 16), resulting in TL emission with various intensities over a wide temperature range, 











































































Figure 16. TL curves for CaSO4:Ln measured using (a) Schott BG-39 filters (330  nm – 620 nm 
transmission) in absolute scale or (b) normalized, or (c) using Hoya U-340 filters (270 nm – 380 nm 
transmission) in absolute and (d) normalized. Only samples for which the TL intensity reached 
values > 1000 counts per integration period (0.2 s) were plotted. 
Figure 17 shows a comparison of the maximum intensity of TL glow curves of this host material 
when doped with different lanthanides using both broad band optical filters. Although CSO:Tm 
showed the highest TL intensity in the UV range, this sample lacked the intense TL peaks for 
temperature above 300 oC. Ce and Gd doped samples showed TL peaks for temperatures above 300 






































































Figure 17. Comparison of maximum TL intensities of CaSO4:Ln (0.5 Gy irradiation) when using 
Hoya U-340 and Schott BG-39 optical filters in front of the PMT. 
 
The results confirm CSO:Ln as one of the most promising materials for temperature sensing, 
because of our ability to introduce different TL peaks using selected dopants, and because of the 
presence of high temperature TL peaks. Ce- and Gd-doped samples have the highest temperature 
peaks in the UV range and the Tm- and Dy-doped samples exhibit the most intense TL peaks in the 
visible range. 
CSO with lanthanide co-doping 
Following the influence of single dopants in the TL curve, we investigated the effect of co-dopants 
in order to introduce TL peaks at even higher temperatures. 
CSO was co-doped with Ce because that leads to UV emission and a TL peak in the high 
temperature range (~500 C), combined other co-dopants (Pr, Gd, Tb, and Tm) to obtain as many 
TL peaks as possible in a broad range of temperature. This selection was based on the 11 
lanthanides investigated previously. 
By co-doping/triple-doping lanthanides with Ce, we were able to produce multiple TL peaks at 
higher temperatures with more intensity compared to the singly doped samples. Figure 18 shows 
how co-doping of CSO affects the TL intensity of the material both in absolute and normalized 
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scales. As observed in Figure 19, the Ce3+ emission is the dominant emission in CaSO4:Ce,Pr and 
in CaSO4:Ce,Gd.  The TL intensity of CSO co-doped with Ce and Pr is higher than the TL intensity 
of CSO singly doped with Ce or Pr. On the other hand, the position of the high temperature peak 
of the co-doped sample seems to have a 20 C shift to the lower temperature comparing to the singly 
doped samples. The results also show that the co-doped sample combines the TL peaks from the 
singly doped samples. Similar observations can be made for Ce and Tb co-doping, and Ce and Gd 
co-doping [38].   






































































Figure 18. TL curves of CaSO4 single-doped with Ce or X, or co-doped with Ce and X, X = Pr, Tb or 
Gd in (a) absolute and (b) normalized scales. 
 
            (a) CaSO4:Ce,Pr                           (b) CaSO4:Ce,Tb                     (c) CaSO4:Ce,Gd 
 
Figure 19. TL emission spectra of (a) CaSO4:Ce,Pr, (b) CaSO4:Ce,Tb and (c) CaSO4:Ce,Gd. 
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In the case of Ce and Tm co-doping, however, the opposite influence is observed. The co-doped 
samples CSO:Ce, Tm showed lower intensity than the Tm-doped sample (Figure 20). The TL curve 
from the CaSO4:Ce,Tm sample shows TL peaks typical of Tm-doped sample (85 C, 150 C and 
250 C) and TL peaks typical of Ce-doped sample (450 C), although shifted to higher temperatures 
[38]. 




































































Figure 20. TL curves of CaSO4 single-doped with Ce or Tm, or co-doped with Ce and Tm in (a) absolute 
and (b) normalized scale. 
 
 
Figure 21. TL emission spectrum of CaSO4:Ce,Tm. 
The possibility of improving the samples for temperature sensing application was also investigated 
by triple doping CSO with Ce, Tb and Tm. Figure 22 shows the TL curves of CaSO4 single-doped 
with Ce, Tb, and Tm, as well as co-doped with all three lanthanides. Although the TL intensity of 
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the triply-doped samples is not as intense as that of the Tm-doped sample (Figure 22a), a much 
wider variety of TL peaks is observed (Figure 22b). Similar to CSO:Ce,Tm sample, it is observed 
from Figure 23 that Tm3+ emission is dominant in the TL emission spectra of CaSO4:Ce,Tb,Tm 
[38].   


































































Figure 22. TL curves of CaSO4 single-doped with Ce or Tm or Tb, or triple-doped with Ce and Tb and 
Tm in (a) absolute and (b) relative scales. 
 
 




Based on the results presented we can conclude that: 
1. In samples co-doped with Tm, the intensity of TL curve is reduced but the position of TL 
peak is shifted to higher temperature comparing to the related singly doped samples (Figure 
20 and Figure 22). 
2. In other co-doped samples, the intensity of the TL from the co-doped sample is increased 
but the position of the TL peak is shifted to lower temperature comparing to the related 
singly-doped samples. (e.g.,  CSO:Ce,Pr) 
3. A multiplicity of TL peaks was observed in all co/triply doped samples. 
Finally, Figure 24 compares the maximum TL intensity of all co/triply doped CSO. The results 
show that CSO:Ce,Gd has the highest TL intensity. CSO:Ce,Tm is not as bright but has the 
highest temperature peak. Being the second brightest sample, CSO:Ce,Pr shows both multiple 
TL peaks as well as having the peak in higher temperature range. Based on the results above, 



































































Effect of alkali metal co-dopant 
Continuing with the development of CSO, we investigated if alkali metals could be used to 
introduce additional defects in CSO and extend the temperature range of this material towards 
higher temperatures. Inspired by the effect of  Li dopant to improve the luminescence emission in 
other materials, we examined the role of Li, Na and K as possible charge compensators in order to 
improve the Ln incorporation into the crystal lattice of CSO [45, 46]. The final goal of this section 
was to codope CSO containing the lanthanides of interest with these three alkali metals. We started 
from Pr as the lanthanide since it has a bright TL peak and its emission can be clearly seen in TL 
emission spectra. Figure 25 and Figure 26  shows how co-doping CSO with alkali metals affects 
the TL properties of the material. In all three samples co-doped with Li, Na and K, the TL intensity 
of of CSO co-doped with Pr and the alkali metal is higher than the TL intensity of CSO singly 
doped with Pr or the alkali metal but this effect is only observed in the lower temperature region, 
and unfortunately the multiplicity of peaks has decreased especially in higher temperatures [38].  



















































Figure 25.  TL curves of CaSO4single-doped with Pr or X, or co-doped with Pr and X, X=Li or Na or 
K. 
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(a) Pr,Li                                           (b) Pr,Na                              (c) Pr,K 
 
Figure 26. TL emission spectrum of (a) CaSO4:Pr,Li, (b) CaSO4:Pr,Na, and (c) CaSO4:Pr,K. 
For temperature sensing applications, we are interested in those samples with multiple TL peaks 
and in the high temperature zones. Therefore, we conclude that co-doping with alkali metals is not 
advantageous at least in case of Pr as a lanthanide co-dopant. In future, this study can be broadened 
to those samples that haves already show high-temperature TL peaks such as CSO:Ce and 
CSO:Ce,Tm. 
Other optimization studies 
Acid concentration 
To investigate the amount of sulfuric acid that results in maximum TL intensity, CaSO4:Ce,Tb 
samples were synthesized by co-precipitation as described by Doull et al. [13] using three different 
amounts of sulfuric acid: the amount that stoichiometrically balances the reaction, CaCO3 + H2SO4 
 CaSO4 + H2O + CO2; an amount that neutralizes the pH upon the conclusion of the reaction 
(145% of the stoichiometric amount), and an amount as in Doull et al. [13] ( 360% of the 
stoichiometric amount). Excess acid was removed by evaporation and calcination of the precipitate. 
The amount of acid that neutralizes the pH was obtained by dropping the diluted acid into the 
mixture of CaCO3 and dopants gradually. We then waited for the solution to reach its balance and 
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read the required pH, as monitored using a digital pH meter (Omega- model PHH-37). The process 
continued until the solution reached the neutral pH (~7). 
Figure 27 shows the TL results from the respective sulfuric acid synthesis amounts. The synthesis 
using 360% of the stoichiometric balance of sulfuric acid had the greatest TL intensity and, as a 
result, was the amount used through the duration of this study. 
 




















































Figure 27. TL glow curves of CaSO4:Ce0.2%,Tb0.2% with different amounts of sulfuric acid as a 
percent of stoichiometrically balanced amount (5oC/s), dose: 0.5 Gy, filter: U340. 
 
To avoid evaporation of the acid excess, we also investigated another method to remove the 
unreacted acid. After the acid was poured into the solution completely, the solution was heated on 
a hot plate at 170 oC for 30 min. Then the solution was cooled to room temperature and poured into 
several test tubes. The test tubes rested at room temperature for 4 h to let the CaSO4 precipitate. 
The liquid was then pipetted from the top of precipitate and the test tubes were rinsed with 
deionized water into a beaker. The solution was then heated at 200 oC until it completely dried. The 
product was annealed in a box furnace at 700 oC for 2 h.  
Figure 28 compares the TL intensity and shape of TL peak for materials synthesized using this 
method to those specimens synthesized with the methods used by Doull et al. [13]. As can be seen 
from the figure, the TL intensity of the sample synthesized via acid separation is slightly more and 
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has a small shift toward lower temperature i.e. ~10 oC and ~20 oC for lower and higher temperature 
peak, respectively. Therefore, for future synthesis this new method can be used. 







































 % (Acid seperated)
 % (Doull et al)
 
Figure 28. Comparison between the TL curve of acid-separation method and the acid-evaporation 
method 
Particle size measurement 
To verify that the particles have suitable properties for temperature sensing (i.e. fast response in 
time), additional investigations were carried out to ensure that the particles are sufficiently small 
(< 13 m).  TL for sieved and non-sieved material is compared in Figure 29. As it can be seen, 
CSO TL curve was not changed after sieving. This can be used as verification that CSO sample 
was not adversely affected after passing through the sieve. SEM images are shown in Figure 30 
and confirm that most particles have at least one dimension <13 µm. 
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Figure 29.  Normalized comparison of the prepared CSO compared with not milled and sieved 
material. Ethanol sieving do not change the TL properties of the material. 
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Figure 30. SEM for CSO. Scaled lines have been added as a help to the reader. The yellow lines are 
approximately 10 µm and green lines are approximately 13 µm. They were added using the scale in 
an image processing software. As can be seen, most of the particles imaged have at least one cross 











FEASIBILITY STUDIES ON METHODS TO CHARACTERIZE THE TL KINETICS 
OF CALCIUM SULFATE   
The objective of this chapter is to investigate the feasibility of various methods to characterize the 
kinetics of the TL in CSO, including the determination of the order of kinetics and the activation 
energy. 
Order of Kinetics 
Dose Response 
Three aliquots of each sample, CSO:Pr, CSO:Tb, CSO:Tm were irradiated with different doses 
(0.1, 0.2, 0.5, 1, 2, 5, 10, 20, 50, 100, 200, and 500 Gy). Apertures were used in front of the PMT 
in the case of high doses to prevent saturation of the PMT and/or counter. In the case of CSO:Tm, 
we could only go up to 200 Gy of irradiation since the TL intensity was very high and close to the 
saturation capacity of the PMT even when using the smallest aperture available in the lab (4 mm) 
as seen in Figure 31.  Example of TL curves for only one aliquot of each sample in both normal 
and log scale are shown in Figure 31. We plotted the log scale to be able to track the position of the 


































































































































































































































































































































































Figure 31. Dose dependence curves in normal and log scale for a,b) CSO:Pr, c,d) CSO:Tb, and e,f) 
CSO:Tm. Correction aperture is used is needed to prevent the PMT saturation. Heating rate: 5 oC/s, 
UV transmitting filter used. 
 
In order to identify the linearity dependence of the TL intensity on irradiation dose, the dose-
response curves of the same samples are plotted (see Figure 32). This is the first step to predict the 
behavior of the traps as they are being filled. 
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Figure 32. Dose-response plot for CSO:Pr, Tb, and Tm. Heating rate: 5 oC/s 
The dose dependence data show the position of the majority of the TL peaks is not shifted as the 
traps are being filled (Figure 31). The dose response plot shows that TL intensity of the maximum 
peak has a linear relationship with the given dose during trap filling for a part of the graph (over a 
wide dose range) as identified in Figure 32 i.e. the slope of the graph of Ln(I) versus Ln(D) (D 
being irradiation dose) is one. To evaluate the kinetic order, we need to take a look at the behavior 
the TL peak as the traps are emptied i.e. step annealing data. For higher does, however, the slope 
of the graph for Pr- and Tm-doped samples is more than one. This behavior is called supralinearity 
and is due to the competition between the traps during the heating stage. Briefly, during heating, 
the electrons released either recombine with holes to produce TL signal or be retrapped in the 
deeper traps. The deeper traps act as competitors for the recombination sites resulting in 
supralinearity [25].   
Step annealing data 
Three aliquots of CSO:Pr, CSO:Tm and CSO:Eu were used for step annealing. We chose CSO:Pr 
and CSO:Tm for their high-temperature, high intensity TL peaks that are well-separated in the low 
temperature zone so we can easily analyze them . Figure 33a and Figure 34a show the step 
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annealing data obtained by pre-heating (50 oC- 500 oC) the samples with the steps of 5 oC. We 
plotted Tm-Tstop graphs to show the peak positions as a function of pre-heating temperatures as can 
be seen in Figure 33b and Figure 34b. 






























































Figure 33. a) Step annealing data obtained from CSO:Pr in 5 oC steps. UV transmition filter used, 
Irradiation: 5 Gy, Heating rate: 1 oC/s. b) Tm-Tstop plot obtained from the step annealing data 

































































Figure 34. a) Step annealing data obtained from CSO:Tm in 5 oC steps. UV transmition filter used, 
Irradiation: 5 Gy, Heating rate: 1 oC/s. b) Tm-Tstop plot obtained from the step annealing data 
In figure above, the peaks are identified with numbers for each sample. Figure 33 shows that for Pr 
doped sample, peaks 4, and 5 have a relatively constant position indicating first-order kinetics (see 
Figure 8). In addition, the behavior of the dominant TL peak; peak 3; in both CSO:Pr and CSO:Tm 
samples is an indicator of non-first-order kinetics (Figure 33 and Figure 34). However, in Tm doped 
sample, the behavior of peak 4 indicates either the 2nd-order kinetics or the close overlap of several 
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peaks. In this case, the definitive conclusions are not possible. The peaks in less than 150 oC are 
not shown in the Tm-Tstop plots, due to low temperature phosphorescence that can  possibly hinders 
the TL signal in that region.          
Initial rise method (IRM) 
As discussed in section 0, three approaches were used to apply IRM to TL data in order to find the 
activation energy. We chose CSO:Eu to compare these three approaches since this sample has a 
single peak that makes it easy for our analysis. Figure 35 shows the step annealing data for CSO:Eu. 
The three approaches will be explained in the following sections using this plot. 
 





































Figure 35. Step annealing data from CSO:Eu in 5 oC steps. Visible light transmition filter used, 
irradiation: 5 Gy, correction aperture: 30 mm, heating rate: 1 oC/s 
IRM/ estimation by eye 
In this approach after plotting Ln (I) versus 1/kT of the step annealed data, we chose to recognize 
the initial part of the graph looking for the most linear, small section of the graph as shown in 
Figure 36a. The slope of the linear part of the graph is –E. If we plot the activation energy values 
versus the Tstop and take  the average value of activation energy data points by fitting a straight line 
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in the most linear initial part of the plot, the activation energy for the TL peak of the Eu doped 
sample can be calculated (Figure 36b). 





























Figure 36. a) Initial rise data obtained from CSO:Eu step annealing curve. The red lines indicate the 
linear part of the graph observing by eyes. b) Activation energy calculated for each pre-heated TL 
curve. The red dashed line shows the average of activation energy in the most linear part the plot 
Constant-temperature  
In this approach, after plotting Ln (I) vs 1/kT, each curve is divided into the temperature zones in 
which the initial part of the graphs have fixed temperature range (Figure 37a). Then, the slope of 
linear fit in each fixed temperature range is read. We continued the fitting until the graph appears 
to be non-linear in that temperature zone, then we shifted the fitting to a new temperature zone. We 
called this approach the “const. temp” method (Figure 37b).                                                             
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Figure 37. a) Initial rise data obtained from CSO:Eu step annealing curve. The zones in which the 
initial rise part of the graph has fixed temperature range is defined by red and black slots . b) 
Activation energy calculated for each pre-heated TL curve using const. temp. approach. 
Traditional approach (<10% Imax) 
This approach is the traditional way of measuring the slope of the initial rise of the Ln (I) vs 1/kT 
graph. In this approach, linear fitting is employed only to the initial part of the graph in which the 
temperature does not exceed 10% of the correspondent Imax as shown in Figure 38. 
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Figure 38. a) Initial rise data obtained from CSO:Eu step annealing curve. Red lines indicate linear 
fits calculated in the Origin 8.6. b) Activation energy calculated for each pre-heated TL curve. 
Comparing the three method used for IRM, one can see that with a good approximation, estimation 
by eyes and constant temperature methods results in the same activation energy. However, E 
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calculated by the traditional method is different perhaps due to the larger initial part of the graph 
chosen that includes the noisy non-linear data. 
IRM for CSO:Pr and CSO:Tm 
In this section, we used two of approaches of IRM to calculate the activation energy of CSO:Pr 
(Figure 39), and CSO:Tm (Figure 40). The step annealing data were shown in Figure 33a and 
Figure 34a. The boxes indicate regions of interest. 




























Figure 39. Calculated activation energy for CSO:Pr using the step annealing data, the average 
activation energy in three regions of interest is calculated 
 


























Figure 40. Calculated activation energy for CSO:Pr using the step annealing data 
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Based on the figures above, the average activation energies for CSO:Pr and CSO:Tm samples are 
calculated and shown in Table 3. For CSO:Tm, regions 1, 2, and 4 have too much peak overlap and 
the peaks are too small to get the accurate data. Equation 3.15 was used to calculate the frequency 
factor.  
Table 3. Results obtained from CSO:Eu, CSO:Pr, and CSO:Tm step-annealing and initial rise analysis 
Sample Peak Average Activation Energy (eV) Frequency Factor Tm (oC)  Tstop Range (oC) 
CSO:Eu 1 1.15 ± 0.01 (4.26 ± 1.05)×1008  300 ± 1 90-120 
CSO:Pr 3 1.17 ± 0.01 (7.28 ± 3.97)×1010  214 ± 5 50- 120 
CSO:Tm 3 1.44 ± 0.01 (3.58 ± 1.62)×1013  220 ± 3 150-200 
 
The maximum frequency factor is expected to be in the range of ~1010-1014 s-1, although values 
outside this range can be found [42]. 
Various heating rate method (VHR) 
Figure 41a shows the TL curves of CSO:Eu for various heating rates. The peak positions (Tm) were 




) versus 1/𝐾𝑇𝑚 was fit (Figure 41b) to obtain activation energy and 
frequency factor as explained in section 0. The results are shown in Table 4. 
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versus 𝟏/𝑲𝑻𝒎  to calculate E from the slope and s from the y-intercept. Optical filter BG-39, 
aperture 30mm, 1 mg of sample was used. 
Table 4. CSO:Eu activation energy and frequency factor obtained from VHR method 
Sample Average Activation Energy (eV) Frequency Factor 
CSO:Eu 1.24 ± 0.09 (1.89 ± 0.14)×1014  
As can be seen from the table above, the calculated E for CSO:Eu is different from the obtained 
result using IRM. This could be due to the effect of thermal quenching (TQ). If thermal quenching 
is occurring, the area under the TL curve decreases as the heating rate is increasing, and the 
measured TL curve would be the Randal-Wilkins function multiplied by the thermal quenching 
function (Imeasured= IRW× ITQ) . Therefore, the corrected TL curve would be the measured data divided 
by the I-TQ curve. Unfortunately, we do not have any data regarding the thermal quenching 
available. Therefore, the presented result for E and s obtained from VHRM is just to show how the 










CONCLUSION OF PART 1 
To conclude the first part of this work, we synthesized CSO with the co-precipitation method and 
the optimal conditions of synthesis were determined. Then, a characterization of the 
radioluminescence and thermoluminescence of Ln-doped samples was provided. In RL, typical 
Ln3+ emission was observed, in addition to Sm2+ and Eu2+ emission. In TL, the emissions were 
mostly from Ln3+, except for Eu2+. Next, we studied the effect of co-doping samples in which the 
TL intensity was higher than the combination of the single-doped samples. In addition, by co-
doping lanthanides, TL peaks over a wide range of temperatures were produced. Moreover, co-
doping lanthanides with alkali metals produced adverse effect for our purpose.  The results of 
material development show that by the appropriate choice of dopant, we can produce samples 
suitable for temperature sensing applications. Based on our result, we proposed CSO:Ce,Pr as the 
most appropriate sample for temperature sensing.  
The kinetics of the TL in CSO was studied with several techniques (dose response, IRM, VHRM). 
In IRM, we used three methods and we concluded that eye screening of graph and the constant-
temperature method result in more accurate E. Finally, E and s was found for the dominant peak of 



















Over the past several decades, developments in synthesis and characterization techniques of 
nanoparticles have shown their utility in various biomedical applications such as bio-imaging [47, 
48], tumor targeting [49], and drug delivery [50, 51]. Among them, gold nanoparticles (GNPs) have 
been investigated over the years for various applications in cancer diagnosis and therapy.  
In particular, GNPs have been proposed as novel candidates for radiosensitizing due to their strong 
photoelectric absorption coefficient and ease of synthesis. The photoelectric absorption cross-
section and, subsequently, the radiotherapy effects of the radiosensitizing agent, are directly 
determined by their atomic radius. In this regard, gold (Z=79) is an ideal candidate for radiotherapy. 
NPs with a larger atomic radius than gold atoms (~0.17 nm) are known to have a strong radiation 
enhancement effects [52]. GNPs injected into patients can be delivered to tumors either by passive 
or active targeting. In passive targeting, GNPs of certain sizes enter into the tumor tissue more 
readily compared to normal tissue due to large size of the tumor’s blood vessel pores, the poor 
lymphatic drainage (movement of lymph fluids around the cells) from the tumor tissue, and the 
leakiness of the newly formed blood vessels in tumors. The consequent effect is called Enhance 
Permeability and Retention (EPR). The EPR effect leads to the blood vessel walls not sealing 
tightly together, leaving enough space (200-800 nm) for GNPs to accumulate in the tumor tissue 
[53]. The active targeting works by conjugating GNPs with a variety of ligands such as antibodies 
or peptides specific to the cancer cells which leads to the binding of targeted GNPs to tumor cells 
with specific antigens or receptors. 
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Molecular Imaging is considered a very important tool for cancer diagnosis, management, and the 
follow up of this disease. Of all the molecular imaging modalities, the two most sensitive non-
invasive ones are nuclear imaging modalities, namely Positron Emission Tomography (PET) and 
Single Photon Emission Computed Tomography (SPECT). As these two modalities are expanding, 
the need for the new agents and strategies to be used with them is also increasing. Moreover, there 
has been a great interest to merge diagnostic and treatment functions within a single tool. The agents 
that can be used as both diagnostic and therapeutic agents (theranostics), such as GNPs, can make 
this interest happen. GNPs have a potential to be easily loaded with a variety of targeting and/or 
therapeutic agents due to their well-developed surface chemistry. 
 However, the same challenges for using GNP for in vivo imaging also hinders their application for 
radiotherapy and other clinical applications. One of the most important challenges is that GNPs 
administered to patients are distributed both to tumors and normal tissues, therefore, without 
accurate and detailed information about the distribution of GNPs in vivo, severe damage can occur 
to healthy tissue when radiotherapy is administered. In addition, toxicity to surrounding healthy 
cells often limits the maximum irradiation dose that can be delivered to tumors [54, 55]. 
Therefore, the second part of this dissertation focuses on this area of research. The main objective 
is to develop novel hybrid GNPs that are suitable for use as radiosensitizers for radiation therapy 
and allow PET imaging to determine their localization. In the following chapters, we focus on the 
synthesis of novel GNPs and their application for bio-imaging. The novel 64Cu (a positron-emitter 
with a half-life of 12.7 h) doped Cu@Au GNPs we are developing have a core-shell (copper core 
and gold shell) structure with the majority of material (>90%) being gold and therefore is expected 
to have similar radiosensitization properties to conventional GNPs. Our hybrid GNPs are inherently 
radioactive (radionuclides are located in the core), therefore, we expect a lower risk of radionuclide 
dissociation, which in turn can lead to more accurate in vivo imaging and will allow us to administer 







Gold Nanoparticles and Synthetic Methodologies 
Historical Background 
Around the 5th century BC, Egyptian and Chinese authors first mentioned solutions of gold (Au) 
and their healing powers. A very famous example of using colloidal Au in aesthetics is the Lycurgus 
Cup, which displays a red color in transmitted light and a green color in reflected light due to gold 
nanoparticles used in its structure (Figure 42)[56]. In the middle ages, soluble gold was used in 
medicine to cure a great variety of diseases such as heart problems, epilepsy and tumors as reported 
in a book by the medical doctor Francisci Antonii in 1618 [57]. Michael Faraday was the first to 
study the gold nanoparticles in a scientific way around 1850. He noticed that the red color of gold 
particles was due to their tiny size and introduced a technique to turn that color to blue [58]. He 
also reported the formation of colloidal gold by reduction of AuCl4 solution by phosphorus in CS2 
[57]. After Faraday, several scientists developed techniques to synthesize gold particles. To date, 
there have been many reports on the size and shape of GNPs varying from nanoshells, nanorods, 




Figure 42. Lycurgus Cup, left-reflected light and right-transmitted light (taken after [61]) 
Synthesis of Gold Nanoparticles 
Gold nanoparticles have a long history in synthesis and characterization. Many properties of GNPs 
are related to the ratio of their surface area to their volume and the spatial confinement of the 
electrons and the electric fields in and around them [62]. In order to make particles with specific 
size and shape, we need to have a good knowledge about the bonds between the particle surface 
and the stabilizing agents. The GNPs are usually formed when the Au(III) salt is available in the 
reaction medium and as long as the stabilizing agents make more bonds with the particle surface 
than the solvent molecules, which will prevent the aggregation of particles. Therefore, the 
stabilizing agent has to have lone electron pairs to ensure binding to the surface of the GNP [63]. 
The potential stabilizing agents that fulfill the mentioned requirements could be chosen from the 
amino acids [64], polymers [65, 66], PEGs [67-71], and proteins [72-74]. The most popular 
methods to synthesize spherical GNPs are as follows: 
Turkevich-Frens method 
The most popular method to synthesize GNPs was introduced by Turkevich [75, 76] in 1951 and 
later modified by Frens in the 1970s [77]. This method consists of reducing of Au(III) in chloroauric 
acid (HAuCl4) by a boiling solution of sodium citrate (60-80 oC) for one hour. The average particle 
size obtained with this method is 10-20 nm and the size can be controlled by varying the citrate/gold 
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ratio. In this method, sodium citrate acts as both a reducing and a stabilizing agent. Due to the non-
covalent nature of the citrate-gold binding, the GNPs obtained by this method can be easily used 
as precursors for the synthesis of other GNPs and the binding can replaced by other molecules of 
interest, such as thiol groups [57, 78]. 
Brust method 
In 1994, Brust and Schiffin introduced another method to make GNPs in solvents with reduced 
dispersity and controlled size [79, 80]. In this method, sodium borohydride is used as a reducing 
agent (reducing Au(III) to Au(I)) and tetraoctylammonium bromide (TOAB) acts a stabilizing 
agent. The reaction of the chloroauric acid with these two agents takes place in toluene. The average 
size obtained by this method is 5-6 nm. However, TOAB can be replaced by a stronger binding 
agent such as thiol to prevent the aggregation of the GNPs, which normally takes place over the 
course of two weeks and is the normal trend of the particles obtained by this method due to the 
weak binding of TOAB to the surface of the GNPs. The soft character of both Au and S allows 
strong binding between the gold and thiolated ligands. By shifting the ratio to thiol/Au, one can 
control the size of core nanoparticles. The larger ratio of thiol/Au leads into smaller core size with 
less polydispersity [Gamma 149, 152, 153]. 
Sodium borohydride reduction method 
So far, this method is the fastest and easiest method of synthesizing GNPs. The method consists of 
reduction of NaAuCl4 (gold salt) by sodium borohydride which is a very strong reducing agent, 
and can produce GNPs even at room temperature. The stabilizing agents that could be used in this 
method involves peptides [81] and proteins [82]. The particle size obtained by this method is 
between 4-25 nm. 
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Gold Nanoparticles in Cancer Diagnosis and Therapy 
Cancer 
Undoubtedly, cancer is one the leading causes of mortality in recent years. The International 
Agency for Research on Cancer (IARC) reports the expected growth rate of cancer worldwide to 
be 21.4 million new cancer cases per year by 2030. Cancer is characterized by an up-regulated and 
increased process of cell growth that leads to the formation of masses, the so called tumors [83]. 
Currently, more than a hundred types of cancer have been diagnosed, each being classified by the 
cells that are involved (http://www.cancerresearchuk.org/cancer-help/about-cancer/what-is-
cancer/).  
Before any type of cancer can be treated, a high-resolution image of the cancerous cells or tumors, 
which can define the location, size and shape of the cancerous tissue, is required. In many cases, 
after the cancerous tissue is surgically resected, residual cancer cells, which are often microscopic, 
can be left behind and increase the reoccurrence rate in the future. In many other cases, cancerous 
cells in their early stages and of microscopic size, and/or the hindrance by other organs, make it 
difficult for the current imaging technologies to target them. Therefore, many researchers have been 
looking for different technologies that can help detect the cancerous cells, tissues and tumors at the 
microscopic scale before or after the surgery, and can image them with high resolution and defined 
margins [84]. 
Cancer Targeting 
As mentioned in previous sections, the targeting of cancer cells can be done using both passive and 
active routes. Overall, targeted therapy and imaging is based on exploiting the receptors that are 
overexpressed in cancer cells membrane. These receptors help us target the cancer cells by 
improving the selectivity and signal of the imaging techniques. A good example of cell membrane 
receptors are peptide receptors. Peptides are small chains of amino acids that are used for targeting 
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the membrane receptors expressed in tumors. Peptide targeting usually works by small peptides 
binding to specific receptors with high affinity. Some of the advantages of using peptides for 
targeting includes, but is not limited to, their small size and ease of preparation, resistance to 
degradation in harsh chemical or radiolabeling conditions, rapid clearance from blood, high tumor 
penetration, and low toxicity. The disadvantages of using peptides include their short biological 
half-life, and the required detailed knowledge of molecular engineering of synthetic peptides. To 
be more elaborate, peptides can be degraded by peptidases and proteases (enzymes that have a role 
in breaking down bigger molecules into smaller parts, i.e. breaking peptides into amino acids in 
this case) when administered in vivo [85].   
Nuclear imaging modalities 
The systematic use of radionuclides in medicine was initiated with the development of the cyclotron 
and nuclear reactors in 1930s. Nuclear Medicine was established due to the potential of producing 
several radioisotopes suitable for medical applications using cyclotrons [86]. Radiopharmaceuticals 
are drugs with some kind of radionuclides existing in their constitution. The radiolabeled 
nanoparticles used for cancer diagnostics and therapy is one type of radiopharmaceutical [87]. 
Radionuclides are atoms of unstable nucleus and excessive energy. A radionuclide releases this 
excess of energy by the  radioactive decay of its nucleus leading to the emission of high energy 
particles such as alpha, beta, positron, and gamma rays. The half-life of a radionuclide (T1/2) is a 
characteristic of each radionuclide and is defined as a time needed for the number of nuclei to 
reduce to half of the initial number. For cancer theranostics (therapy and diagnostics), the selected 
radionuclide should have the appropriate half-life along with the desired emitted radiation and/or 
particle [88-90]. 
Due to high ionizing energies and low tissue penetration, the α or β- emitting radionuclides are used 
as therapeutic radiopharmaceuticals. An example of such a radiopharmaceutical is the first FDA-
approved, α-emitting 223RaCl2 for bone metastases therapy. However, γ or β+ emitting radionuclides 
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are more suitable for the development of diagnostic radiopharmaceuticals to be used with PET or 
SPECT [91]. 
PET imaging is a nuclear medicine functional imaging technique that is used as an aid to the 
diagnosis of cancer. This imaging technique works with the use of β+ emitting radiopharmaceuticals 
and is based on the detection of two photons of 511 KeV energies simultaneously.  These photons 
are produced from the annihilation of the positrons and electrons in the medium. 18F with a half-
life of 110 minutes is the most common radionuclide used with PET. SPECT is another nuclear 
imaging technique that relies on the use of γ-emitting radionuclides with energies between 30-300 
keV. 99mTc is the most used SPECT radionuclide [92].  
64Cu is specifically an isotope of interest for both radiotherapy and PET imaging due to favorable 
emission characteristic (t1/2= 12.7 h, β+ 17.4%, Emax= 0.656 MeV). The short positron range of this 
isotope compared to other positron emitters makes 64Cu a better candidate for producing high-
resolution images. In addition, its longer half-life is an advantage over other positron emitters (e.g. 
18F) for both imaging and therapy purposes, where longer circulation times are necessary to achieve 
optimal target uptake [93].  
The development of a non-invasive imaging tool for monitoring the distribution of GNPs in vivo 
is critical for successful applications of GNPs in the progress of basic biology research as well as 
clinical research. Techniques of directly labeling GNPs with radioisotopes are currently available 
and this is usually done using γ-emitting radionuclides [94, 95]. However, this method requires 
binding linkers between GNPs and radionuclides, which can further alter the outer structure of the 
GNPs. This change may affect the radio-sensitization properties of the GNPs and alter the 
intracellular uptake and biodistribution of the radiolabeled GNPs compared to those that are not 
labeled. Additionally, the possible detachment of radioisotopes from GNPs may lead to erroneous 
estimations of GNP distributions considering that these detached isotopes are counted as GNPs [96, 
97]. In order to utilize the highly sensitive nuclear medicine modalities, GNPs are often externally 
labeled (radiolabel) with radionuclides before patient administration and PET or SPECT in vivo 
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imaging is obtained. These external radiolabeling methods are not always stable which may lead to 
the dissociation (or separation) of radionuclides from the GNPs. 
Nanomedicines 
Nanotechnology is a wide filed involving engineering, physics, chemistry, biology, and medicine 
and includes designing, characterizing, producing and applying the nanoscale devices and systems. 
Nanoparticles have high particle numbers per mass and larger surface area comparing to 
microparticles that enhances their reactivity in chemical reactions [98-100]. Nanoparticles can be 
produced by the use of a large variety of other materials from inorganic metallic compounds to 
organic polymers [101]. Figure 43 shows some example of different types of nanoparticles.  
 
 
Figure 43. Examples of different types of nanoparticles for biomedical applications [102] 
 
Nanomedicine is a field of science that utilizes nanoparticles or devices for monitoring, diagnosis, 
and treatment of diseases. The main applications of nanomedicine are for drug delivery, 
regenerative medicine, and in vitro and in vivo imaging. In vivo imaging includes MRI, ultrasound, 
optical imaging, PET, and SPECT [103, 104]. Compared to conventional drugs with adverse effects 
or lack of effects due to improper/insufficient dosage (e.g. chemotherapy drugs), nanomedicine 
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allow a more efficient drug accumulation at the target size due to their small size and ease of 
penetration into tissue barriers, leading to the reduction of the unwanted adverse effects and toxicity 
of the cancer drug [105, 106].   
The integration of radionuclides in nanoparticles can happen either with conjugating the chelating 
agents to the core of nanoparticles for the coordination of radionuclides, or with encapsulating the 
radionuclides inside the nanoparticles. The stability of radionuclide incorporation is very important 
for nuclear imaging and therapy during the in vivo administration, otherwise, the imaging data will 
no longer reflect that of the nanoparticles [107] . 
Some of the radiolabeled nanoparticles developed for nuclear imaging applications are presented 
in Table 5. 
Table 5. Examples of radiopharmaceuticals and their application in imaging 
Nanoparticle Radionuclide Imaging Reference 
Iron Oxide NPs 18F PET/CT  [108] 
Quantum Dots 18F Multimodal  [109] 
Quantum Dots 64Cu PET/NIRF [110, 111] 
Carbon NPs 111In SPECT [112] 
 
The advantage of using nanocarriers in cancer imaging is that they can increase the uptake of the 
agent due to passive targeting as well as the ability to conjugate nanocarriers to biological agents 




Figure 44. A: Passive targeting work based on “Enhanced Permeation and Retention” (EPR) effect, 
B: Active targeting works based on attaching the ligands that only bind to specific receptors on the 
cell surface as explained in Error! Reference source not found., taken after [[113]] 
GNPs in cancer theranostics 
GNPs have been widely researched as pharmaceuticals for cancer theranostics (therapy and 
diagnosis). GNPs are biocompatible due to resistance to oxidation under physical and biological 
conditions. They also possess unique optical properties that can be controlled by their size and 
shape. Furthermore, they offer multiple functionalization with biomolecules for targeting tumor 
cells [57, 114]. All these properties make GNPs promising agents for cancer imaging and therapy. 
GNPs can be used as Computed Tomography (CT) contrast agents for cancer diagnosis since gold 
can absorb the X-ray energy at a higher ratio than its surrounding cells (approximately 100 times) 
due to its high atomic number [115].  Figure 45 shows the micro-CT scan of kidneys in a live mouse 





Figure 45. micro-CT scan of kidneys in a live mouse using a) gold nanoparticles, and b) iodine 
contrast agent (Omnipaque H ) as contrast agent 
[http://www.nanoprobes.com/newsletters/ImgGold.html] 
 
Besides imaging modalities, GNPs are applied as therapeutic agents. GNPs are good candidate 
sensitizers for radiation therapy. After GNPs are bombarded with radiotherapy beams, they interact 
with the radiotherapy primary beams resulting in the cascades of secondary radiation (i.e. 
electrons). The secondary radiation produced by this interaction provides radio-sensitization for 
cancer cells that are impregnated with GNPs. The concept behind using GNPs as the 
radiosensitizing agents well be discussed in more detail in the next section.  
Another application of GNPs as therapeutic agents is for photothermal therapy. GNPs can reach 
temperatures of 70- 80 oC when irradiated by laser pulses with appropriate wavelength leading to 
the destruction the cancer cells [116, 117].  
Besides imaging modalities and therapeutic applications, GNPs can also be conjugated with various 
chemo drug molecules for targeting specific tumor cells [118-125]. For example, GNPs have been 
used as a carrier of the cytotoxic drugs such as doxorubicin (a bacterial antibiotic that is widely 
used to treat leukemia and various other forms of cancer). When used as drug delivery platform, 
GNPs can enhance the cytotoxicity of the molecules they are carrying by shielding the drug and 
avoiding its degradation in the healthy tissues, the so called “bioavailability” effect [126, 127]. 
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So far, three generations of GNPs have been developed for cancer theranostics. The first generation 
are the GNPs produced based on basic surface chemistry. The second generation of GNPs are the 
ones that are coated with polyethylene glycol (PEG) exhibiting improved stability and optimized 
surface chemistry. This generation allows the passive targeting through the EPR effect. The third 
generation corresponds to the GNPs modified by bioconjugation such as peptides for active 
targeting [128, 129].  Figure 46 shows the schematic of these three generations.  
 
Figure 46. Schematic of the three generations of GNPs (taken after [61]) 
GNPs as radiosensitizers 
Radiotherapy is a commonly used treatment with application rate as high as 80-90% for several 
types of cancers such as breast cancer[130, 131]. In a radiosensitization process, radiosensitizers 
present at the tumor location interact with irradiation dose and/or the biological targets to enhance 
the effect of radiotherapy via physical, chemical, and biological mechanisms. GNPs have been 
known as potent radiosensitizers due to their exceptional physical and chemical properties [131-
133]. 
The physical basis of GNPs radiosensitization come from the fact that metal-based nanoparticles 
such as GNPs, with high Z, enhance the contrast between tumor and soft issues, thus decreasing 
side effects compared to radiotherapy alone [134].  
The physical interactions between radiation and nanoparticles happen through three mechanisms: 
1) photoelectric effect usually followed by Auger cascades, 2) Compton effect, and 3) pair 
production.  The photoelectric effect dominates at lower energies of the incident photon (10-500 
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keV), leading to the ejection of an electron from the inner atomic orbitals. The vacant orbit is filled 
by an outer shell electron with high energy, causing the release of low-energy photons that in turn 
release secondary electrons (Auger cascade).  This process has the major contribution in causing 
ionizing events. The photoelectric absorption cross-section is proportional to Z3-5. Therefore, 
materials with higher Z, such as gold, have higher mass energy absorption coefficient compared to 
materials with low Z. The absorbed radiation energy is released locally by the emission of photons 
and secondary electrons causing damage to biological components around them [84, 135].  
Biological Properties 
Toxicity 
GNPs have been widely examined for in vitro and in vivo biocompatibility [136-139]. The toxicity 
of GNPs depends on their shape, size, surface charge and surface coating but the general toxicity 
of GNPs is in an acceptable level [140-144]. However, since anything can be toxic at high-enough 
doses, we need to examine thoroughly how toxic our synthesized GNPs are at the concentrations 
they might be possibly used in future. Hence, it is mandatory to evaluate the cell viability and 
cytotoxicity of 64Cu@Au GNPs by investigating their effects in human cells.  The toxicity of GNPs 
can be shown with half-maximal inhibitory concentration (IC50) which is a quantitative 
measure that indicates how much of GNPs is needed to inhibit a given biological process 
or biological component (i.e. cells viability) by 50%. 
Biodistribution 
The biodistribution information will allow us to administer the radiotherapy with a pre-knowledge 
of the clearance characteristic of our material.   
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Pharmocokinetics 
Pharmacokinetics (PK) data are useful for gaining insight into the clearance of drug from the blood. 
PK studies is the type of study describing the time course and factors affecting the handling of 
drugs by the body until its complete elimination [145]. In other words, by PK analysis, we can 
extract information regarding what the body does to the drugs by calculating the rate of drug 
absorption (entry into blood circulation), distribution (dispersion or dissemination in fluids and 
liquids), metabolism (irreversible decomposition into daughter metabolites), and excretion 
(elimination of the substances from the body). A typical PK graph relates the time course of 
administration to the drug concentration in the body. 
There are several models for PK analysis. We will be using the simplest model (one compartment 
model) throughout this dissertation. This model uses the following equation to give a concentration 
(amount per volume) as a function of time. 
                                               𝐶 = 𝐶𝑚𝑎𝑥𝑒
−𝜆𝑡                                                                        (0.1) 
where C is the concentration, Cmax, 𝜆 is the elimination rate constant, and t is time. 
Figure 47 Shows an example of a PK graph when the drug is injected in the body by intravenous 
(iv) route.  
 
Figure 47. Schematic of an expected PK graph 
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Objective of this study 
We were motivated to develop hybrid GNPs with radiosensitizing and PET/SPECT imaging 
capabilities. The hybrid NPs we developed have a core-shell structure with the majority of material 
(> 95%) being gold. The core is made of Cu, which was then covered with an Au (gold) shell.  
The hybrid GNPs have the potential as image-ready GNPs. When GNPs first commercially became 
available, they were provided as bare GNPs. Due to their increasing popularity in biological and 
medical applications, most companies now provide them as PEGylated-GNPs with linkers. When 
doped with radionuclides, the core changes to positron emitters, which allows for imaging using 
PET.  
In the following chapters, we first report the development and characterization of non-radioactive 
GNPs confirmed by TEM, UV-vis and ICP. Our hybrid GNPs were functionalized with varying 
amounts of c-Met binding peptide (cMBP) to specifically target Mesenchymal-epithelial transition 
factor (c-Met). c-Met is a receptor that is expressed in many human cancer cells such as the A549 
human lung cancer cells. Later, we produced radioactive hybrid GNPs by doping them with 64Cu 
and evaluate their binding properties in cell binding studies.  
Simultaneously, GNPs were traced by Gamma detection. The radioactive hybrid GNPs were then 
injected into animals for studying their biodistribution and pharmacokinetics. 
The radiolabeled hybrid GNPs are inherently radioactive, therefore, there is no risk of detached 
radiolabels being counted erroneously. Since our hybrid Cu@Au GNPs (in which the shells are 
gold) have identical outer structures to that of regular GNPs, the existing GNP targeting and nano-
carrier methodologies can be utilized. This allows an easy transition of the technology into basic 








MATERIALS AND METHODS 
Synthesis of core-shell Cu:Au GNPs 
The procedure of synthesis we used is the modification to the synthesis process used by Zhang et 
al. [146]. Briefly, aqueous solutions of CuSO4 and sodium citrate were added to 20 ml of water at 
12 ± 2 o C while stirring at 1,000 rpm. Then 1 mL of freshly prepared NaBH4 solution was rapidly 
added to the reaction mixture. After 15 min, HAuCl4 solution was added to the reaction mixture 
and continued stirring for another 20 minutes. The optimized conditions for the formation of 
Cu@Au GNPs are shown in Table 6.  The final product had a red-wine color as shown in Figure 
48. Next, the final product was treated by size-exclusion chromatography (also known as gel 
filtration) to remove the excess salts and unreacted molecules. In the final step, the GNPs were 
functionalized with PEG only or with PEG and cMBP peptide for targeting purposes.  
Table 6. Optimized condition for the formation of unfunctionalized Cu@Au GNPs 
 
Chemical Molarity (M) Volume  
Water   20 ml 
CuSO4 0.1 50 µl 
Sodium citrate 0.1 150 µl 
NaBH4 0.025 2 ml 






Figure 48. The reagents and final products in synthesis GNPs 
Peptide synthesis 
As discussed earlier, peptides are being used for in vivo cancer detection due to their ability to 
increase the tissue-specific uptake. The c-Met is overexpressed by many cancer cells such as lung, 
breast, prostate, head and neck, ovarian, renal, melanoma and many more [147-150]. The following 
steps show the synthesis procedure for functionalizing the GNPs.  
1. The cMBP, Lys-Ser-Leu-Ser-Arg-His-Asp-His-Ile-His-His-His, identified from a phage 
display of a combinatorial peptide library by Kim et al. (2007) was used as a c-Met 
targeting vector to functionalize our novel 64Cu doped hybrid Cu@Au GNPs [151]. 
2. The c-Met binding peptide conjugate, cMBP-(PEG2)3-Cys-NH2, was synthesized on  an in-
house built peptide synthesizer [152]. The peptide conjugate was purified by HPLC and 
characterized by matrix-assisted laser desorption/ionization (MALDI) mass spectrometry. 
Figure 49 shows the MALDI -mass spectrum of the cMBP-(PEG2)3-Cys-NH2 performed 
at OUHSC core facility.   
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3. In the final step, our hybrid Cu@Au GNPs were functionalized with varying amounts of 
cMBP to specifically target c-Met. The schematic is drawn in Figure 50.  
 
 
Figure 49. MALDI mass spectrum of cMBP-(PEG2)3-Cys-NH2 (MW – 2,040.7) 
 
 
Figure 50. Schematic of Cu@Au GNPs functionalized with cMBP to target c-Met 
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Radiolabeling 
All experiments involving radioactivity were performed after thorough planning and a dry run, in 
compliance with the regulation of OUHSC and ALARA (as low as reasonably achievable) 
radiation-protection principle. 64Cu was purchased from Washington University School of 
Medicine cyclotron facility. The radiolabeling process was carried out in a lead-shielded fume 
hood. The synthesis procedure was the same as that reported in section 0 with the addition of 64Cu-
chloride aqueous solution according to the activity needed for each experiment. 
Material Characterization 
The following sections will review some basic principles of the characterization techniques used 
in this study. 
Ultraviolet-Visible Spectroscopy 
Ultraviolet-Visible Spectroscopy (UV-vis spectroscopy) is a commonly used technique to 
characterize GNPs. UV-vis spectroscopy is a reliable technique to study and identify GNPs since 
GNPs inherit optical properties that vary with their size, shape, concentration, and the index of 
refraction near their surface. The optical absorbance peak of the GNPs was measured using a Cary 
5000 UV-Vis-NIR spectrophotometer (model Cary 5000, Varian).  
The color transitions in GNPs is correlated to the size or the thickness of a shell in a core-shell 
structure. Most of these transitions occur in the visible portion of the spectrum and can provide 
information about the size and the morphology of the particles [153]. 
Transmission electron microscopy (TEM) 
Transmission electron microscopy (TEM) is a more advanced technique to determine the size, 
shape and arrangement of GNPs that allows direct imaging of the particles. In a typical TEM 
measurement, a focused beam of electrons is transmitted through the sample leading to the 
formation of an image in a similar way to a light microscope. The samples were prepared by 
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dropping 2 μl of GNPs onto a carbon-coated copper grid and letting them air dry for 4 minutes. The 
grid was then mounted in the instrument (JEOL, JEM 2100). The images of the nanoparticles were 
obtained with different zooming modalities of the instrument. The light areas of the TEM images 
indicate the parts of the grid where that material is less dense and therefore more electrons have 
passed through. 
TEM/EDS 
Further studies were performed with the intention of getting more information regarding the 
core/shell structure of the Cu@Au GNPs by combining TEM with Energy Dispersive X-ray 
Spectroscopy (EDS). EDS is a spectroscopic technique that offers information on the elemental 
composition of a nano-sized area [61]. Both TEM and TEM/EDS measurements were carried on at 
the OSU electron microscopy laboratory.  
Inductively Coupled Plasma atomic emission spectroscopy (ICP) 
ICP is the best technique for quantifying the metals present in GNPs. ICP can detect metals like Au 
and Cu over a wide range of concentrations. ICP measurements were performed at OSU soil, water 
and forage analytical lab by using Spectro Arcos.  
X-ray Photoelectron Microscopy (XPS) 
XPS can provide information about the nature of Au bonds as well as surface analysis. In a typical 
XPS measurement, the samples are irradiated with mono-energetic X-rays leading to 
photoelectrons emitted from the surface. An energy analyzer is used to detect these photoelectrons 
to determine their binding energy and the respective intensity 
[http://www.casaxps.com/help_manual/manual_updates/xps_spectra.pdf]. The XPS samples were 
prepared by dropping the material on cleaned silicon wafers and allowing them to dry in air.
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In vitro studies 
Cell binding studies 
In vitro cell binding studies were performed to determine the binding affinity of cMBP-GNPs to c-
MET expressing cells and optimal mount of peptide functionalization. In the first method, different 
peptide-functionalized (0%, 1%, 3%, 5%, 10% functionalization of the estimated Au atoms present 
on the surface) nonradioactive GNPs and the A-549 cells (1×106 cells/well) were incubated in 6-
well plate. After 45 minutes, the cells were washed with PBS three times to remove the residual 
GNPs that are not taken by the cells. Then, the cells were digested with NaOH(0.1M)/SDS(0.1%) 
and collected and submitted for ICP measurement to determine the Au/Cu concentrations. Due to 
the insignificant results, the whole experiment was repeated for 1 h and 4 h incubation time.  
In the second method, the same procedure was followed with radiolabeled GNPs. The same 
concentration of peptide (0%, 1%, 3%, 5%, 10%) was bound to the radiolabeled 64Cu@Au GNPs. 
An activity of 1 μCi was added to each well. The cells were incubated for 2 h before measuring the 
cell-bound activity using a gamma counter. The result is reported in section 0. 
Cytotoxicity 
A-549 cells were seeded in a 96-well plate at 3×103 cells per well. The cells were then cultured in a 
standard condition in an incubator for 24 h. Different concentrations of Cu@Au GNPs (1,000, 750, 
500, 250, 100, 50, 25 μg/ml diluted in RPMI medium) were then added to the wells, and the cells 
incubated for 48 h. After that, MTT was added to each well. Finally, a plate reader (Synergy 2, BioTec) 
was used to evaluate the in vitro cell viability/toxicity profile.  
An MTT (reagent 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide (Alpha-Aesar) 5 
mg/ml in PBS) was used for MTT assay. The MTT assay determines cell viability by measuring the 
activity of living cells via mitochondrial dehydrogenases.  Unlike traditional methods, which evaluate 
toxicity based on dye uptake in treated non-viable cells, this method provides greater sensitivity and 
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accuracy.  The viability of the control cells was considered 100%, with treated cell viability expressed 
relative to the control.   
In a typical NP cytotoxicity experiment, 20 μl of MTT is added to each well, following by a rest time 
of 2 h to let the cells absorb the MTT. The live cells then turn the yellow color of MTT to blue. The 
cells are digested in 100 μl of Dimethyl sulfoxide (DMSO)/well and the optical density is read at 570 
nm to record the viability. However, for the GNPs we developed, we could not use the typical method 
since the color of GNPs are red and this makes it difficult to see the optical absorbance. Instead of 
adding MTT to the wells, first we had to empty the GNPs and medium from the top of each well 
carefully. For that purpose, we used a vacuum pipe that was installed in the cell culture fume hood. We 
used extra caution not to vacuum the cells from the well. Then, 20 μl of MTT diluted in 100 μl of 
medium was added to each well and the plate reading was followed. The result was used to calculate 
IC50 as shown in section 0. 
In vivo Studies 
All animal studies were carried on following the protocol approved by (Institutional Animal Care 
and Use Committee (IACUC)). We performed the biodistibution studies using a mice model and 
pharmacokinetics on a rat model, as described in the following sections. 
Biodistribution 
A preliminary biodistribution study was performed to investigate what organ/organ-systems are 
responsible for clearance of 64Cu@Au GNPs from the blood. For this purpose, healthy CD-1 mice 
were used. Different doses of 64Cu@Au GNPs were injected into the tail vein of the mice under 
isoflurane anesthesia. For each data collection time, four mice were injected and the injection dose 
was different for each data time:  1h (10 μCi/mouse), 4h (15 μCi/mouse), 24 h (50 μCi/mouse) and 
48h (100 μCi/mouse) (n=4 mice/timepoint; Total=16). At each time point after injection, mice were 
euthanized by cervical dislocation and various organs were collected to determine the activity 
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present in the tissue (using a well-counter). The activity was normalized to the weight of the tissue 
and presented as the percentage of the injected dose per gram of tissue and subsequently as the 
percentage of injected dose per organ. 
Pharmocokinetics 
In order to determine the pharmacokinetics of 64Cu@Au GNPs, male Sprague Dawley rats were 
used. Rats of 200-225 g weight have optimal size for the installation of indwelling femoral artery 
catheter. This catheter can be used to sample blood at intervals to determine the clearance rate of 
64Cu@Au GNPs. 7 rats were injected with different amount of 64Cu@Au GNPs while the injection 
dose was kept the same ~ 40 μCi for all injections. In order to have a good statistical data, 3 rats 
were injected with 5X (X= concentration of GNPs) and 4 rats were injected with 3X. The sampled 
blood of 7 rats were collected according to the following volume and time points:  0.1 ml at 2 min, 
5 min, 10 min, 20 min, 30 min, 1 h, 2 h, 4 h , 6 h,  0.3 ml at 24 h, 0.6 ml at 28 h and 48 h. The 
sampled blood was the counted by a gamma counter (Ludlum Measurements Inc., Model 2200 
Scaler Ratemeter). The activity was then corrected for decay based on the standard counts and for 





RESULTS AND DISCUSSIONS 
Synthesis and Characterization of Cu@Au GNPs 
Based on optimum condition listed in Table 6 we synthesized the GNPs. The characterization 
results are as the following. Figure 51 shows the UV-Vis spectra of three different samples. The 
absorbance peak appeared around 526 nm, which is the typical absorbance peak of gold. We 
observed that upon addition of HAuCl4, the solution turned wine red instantly. These results are in 
line with the results obtained by Zhang et al. As suggested by them, during the synthesis, the 
galvanic displacement reaction between HAuCl4 and Cu nanoparticles takes place following by 
reduction of HAuCl4 by the remaining NaBH4 after generation of Cu NPs. They also observed the 
same color change (the solution turning wine red immediately) upon the addition of HAuCl4, 
indicating a prompt growth of Au shell onto the Cu NPs core. In addition, they further more 
investigated that the absorbance of HAuCl4 centered at 218 and 293 nm disappeared after the 
reaction, and a new absorbance band emerged at 520 nm which is the feature of gold surface 
Plasmon resonance SPR. In their experiment, after 24 h the new gold SPR band was extended to 
530 nm and became a little more intense displaying a quick growth of Au shell onto the Cu NPs 
core. This could be an indicator of a complete transformation of AuCl4 to clusters of Au atoms, 
with an average size above 2 nm that confirms the color of our synthesized Cu@Au GNPs  and the 
UV-Vis spectra  we obtained  within the 24 h of synthesis [146] .  
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Figure 51. Absorbance peak of Au around 526 nm confirmed by UV-Vis spectrometer for different 
samples 
TEM measurement was performed to assist the understanding of the shape, size and the distribution 
of both stable GNPs and the radiolabeled GNPs after the complete decay of 64Cu. The Cu@Au 
GNPs 2 h post synthesis were more irregular in geometry and more separated with average size 
smaller than 10 nm (Figure 52 a, b). After 24 h, more regular, spherical particles occurred, with a 






               




Figure 52.  a) TEM on GNPs after 2 h, magnification: 150K. b) Distribution of GNPs after 2 h, 
magnification: 20K. c) Distribution of GNPs after 24 h, magnification: 40K . d) GNPs showing 
spherical shape after 24 h, magnification:  800K. 
 
The radiolabeled 64Cu@Au GNPs shows the same average size, distribution and morphology as the 
stable Cu@Au GNPs as shown in Figure 53.   
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Figure 53. TEM on the radiolabeled GNPs after decay. Average size is less than 10 nm, 
magnification: 250K 
 
We performed TEM/EDS (energy dispersive X-ray spectroscopy) analysis on different parts of the 
grit to obtain more detailed information about the copper and gold distribution in the sample. To 
reduce the effect of the presence of Cu in parts of the electron microscope and in the grits, we used 
Ni grit and the background was subtracted (a value typically found on empty grits and on areas not 
containing particles). Also, due to the small size of particles (< 10 nm), and the limitations in the 
magnification of our device, we were not able to take the measurement from one particle only. 
Therefore, the reported quantities is only from a micrometer-sized areas of the grit containing 
several particles rather than just one particle.  The TEM/EDS spectrum from a partial region of 
Cu@Au GNP sample is shown in Figure 54. The result showed the presence of X-ray dispersion 
energy peaks characteristic of gold (Au(M) ≈ 2.120 keV, Au(Lα) ≈ 9.712 keV), as well as less 
intense characteristic X-ray dispersion energy peaks of copper (Cu(Lα) ≈ 1.00 keV, Cu(Kα) ≈ 8.00 
keV). These results are similar to the results of EDS analysis of nanoparticles containing Au and 




a)                                                              b) 
          
Figure 54. a) TEM and b) EDS analysis of Cu@Au GNPs on a micrometer sized areas of a nickel grit  
The values of Au and Cu present in the micrometer-sized area of the grit was measured several 
times from different parts of the grit and the average is shown in the following Table.                
Table 7. The average percentage of Au and Cu present in the microemeter sized area of the grit 
Cu@Au GNPs/PEG  Gold Copper 
Average 23.57 % 76.43 % 
The XPS analysis can be used to confirm the core/shell structure of GNPs with a good 
approximation. As seen in Figure 55a, Au 4f7/2 XPS spectrum exhibited a binding energy (EB) at 
84.3 eV with a well-separated spin-orbit components (Δ=3.7eV), consistent with metallic gold atom 
binding energy (Au0, EB=84.0 eV).  The shift of binding energy for Au 4f7/2 when compared to 
that of zero-valance gold atom(84.0 eV), could be due to an electronic modification of the Au atoms 
by Cu NPs [146, 156]. Figure 55b shows that the EB for Cu 2p3/2 XPS was located at 933.3 eV. 
Cu2p peak has a significant spin-orbit split components (Δ=19.75eV) which is consistent with Cu0 
and Cu(I) oxide (EB=933.0 eV). This observation shows that majority of Au and Cu present in the 
nanoparticles are in their zero valence state [157]. The database used to compare the binding 
energies are taken from https://xpssimplified.com/periodictable.php. 
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Figure 55. XPS spectra for a) Au 4f, and b) Cu 2p in Cu@Au GNPs 
Table 8 represents the ICP result for several samples used in this study. The ratio of Au/Cu is in 
the range of 7.6- 11.5. In addition, based on the numeric result obtained from ICP, more than 50% 
of the initial Au and more than 90% of the initial Cu was used in the reaction. This result is solely 
based on the assumption that Au atoms are all in the shell and by calculating the approximate 
number of Au atoms on the surface from the average particle size and the atomic radius of gold. 












GNP before passing through size-exclusion 
column 11.60 1.53 116.0 15.3 7.6 
Colored GNP after passing through size-
exclusion column 3.76 0.42 37.6 4.2 9.0 
GNP used for PK studies, 5X concentration 4.06 0.38 13.5 1.3 10.8 
GNP used for PK studies, 3X concentration 8.27 0.82 82.7 8.2 10.1 
GNP used for cytotoxicity  11.96 1.04 1495.1 129.5 11.5 
GNP evaporated and filtered for targeting 14.18 1.49 1418.0 148.7 9.5 
In vitro studies 
The result of ICP for digested cells after 1 h and 4 h incubation with functionalized GNPs did not 
show any significant trace of Au and Cu that is the indicator that no uptake was taken place. This 
can be due to several factors ruling the cell uptake. Among all reasons, the most trivial ones are 
peptides not binding to the GNPs, and c-Met expression not being well defined on the A549 cells. 
However, due to the lack of time and the expertise of the author in the field, we decided to continue 
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the rest of the studies with unfunctionalized GNPs. Targeting the cells with radiolabeled GNPs did 
not give us any meaningful result as for the cell uptake either.  
Cytotoxicity 
Figure 56 shows the effect of Cu@Au GNPs on A-549 cell viability. IC50 is the concentration at 
which viability equals to 50% of maximal viability. The 50% of maximal viability was calculated 
as maximal viability- 50% (maximal viability- minimal viability) [158]. The IC50 of our hybrid 
Cu@Au GNPs was found to be 807.2 ± 0.05 μg/ml. This result is within the range reported in 
literature (i.e. 500 - 1,200 μg/ml) based on the NPs size (<15 nm)for different cell types [159, 160]. 
However the IC50 reported in literature for bigger GNPs (50-90 nm) are between 15-20 μg/ml [161] 

























Figure 56. The cell viability was measured by MTT assay. Each point represents the mean viability of 
6 wells. The viability was calculated as the percentage of the viable cells compared to the untreated 
control cells. 
Biodistribution 
The uptake and the clearance of the 64Cu-labeled Cu@Au GNPs were determined through 
biodistribution studies. The data for various organs uptake at 1 h, 4 h, 24 h, and 48 h post injection 
are shown in Figure 57. The highest accumulation of radioactivity at all times were found in the 
liver and the intestine indicating that the 64Cu@Au GNPs are primarily clearing from the blood 
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pool via hepatobiliary pathway. The clearance of the 64Cu@Au GNPs through the kidneys in the 
bladder/urine was found to be low. A negligible uptake of 64Cu@Au GNPs was observed in brain 
and spleen. With the exception of muscles, bladder and spleen, all organs showed an increase in 
64Cu@Au GNPs accumulation between 1- 4 h and the radioactivity accumulation started to 
decrease 4 h post injection. This observation in some organs (uptake of 1 h is less than of 4 h) is in 
contrary with the usual uptake of free 64Cu reported in several publications stating a steady decrease 
in the uptake of 64Cu [93, 162, 163]. To know the reason for this behavior of 64Cu@Au GNPs 
requires more in vivo studies. The uptake of 64Cu@Au GNPs in the muscle is most likely due to 
the blood-associated radioactivity. Collectively, this data indicates that our 64Cu@Au GNPs may 
find potential application in the treatment of the tumors located in the breasts when GNPs are 
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Figure 57. Biodistribution of 64Cu@Au GNPs in mice, n=4 for each time point a) percentage of 
injected dose per gram tissue b) percentage of injected dose per organ 
Pharmacokinetics 
The rats were randomly divided into two groups of 3 and 4. Three rats were injected with 5X 
concentration of 64Cu@Au GNPs and four rats were injected with 3X concentration of 64Cu@Au 
GNPs. The pharmacokinetics were calculated based on average data for each group.  The 
pharmacokinetic data measured included the area under the concentration–time curves from time 
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zero to infinity (AUC0–∞), and the area under the first moment curve (AUMC). Maximum GNP 
concentration (Cmax) was taken directly from the concentration-time plot. The Mean Residence 
Time (MRT) is the average time that the GNPs remain in the body and was determined by dividing 
AUMC by AUC. The Total Clearance (Cl) value was calculated as the dose/AUC0–∞. The average 
decay-corrected injected dose is 40 μCi. In addition, the volume of distribution at a steady-state 
(Vss) was calculated as MRT×Cl, and the apparent elimination rate constant (kel’) was calculated 
as 1/MRT. Finally, elimination half-life (t1/2) is defined as the amount of time required for the 
amount of drug in the body to decrease by 50% and was calculated as t1/2= 0.693/ kel’. 
The concentration-time curves are shown in Figure 58.  
 
 
Figure 58. The concentration vs. time curves for the average data for two different concentration of 
radiolabeled GNPs with constant activity. Red curves show the fitted curves. 
 
The AUC0–∞ was calculated using the AUC0–last  and then extrapolating to infinity by the addition 
of AUClast–∞ as shown in equation below. The graph from which AUC0–last (total AUC) is calculated 
is presented in Figure 60. 




where λ is the terminal slope from semi-log concentration-time graph as seen in Figure 59. 
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Figure 59. The semi-log plot of concentration-time to find the terminal slope 
 
 
Figure 60. Total AUC (AUC0–last) represented by pink area after the fitted curve was extrapolated to 
infinity using λ. 
 
Figure 61 represents the first moment of the data, i.e. the area under the “concentration*time- time” 
curve (AUMC) and the fitted plot. The method to extrapolate the curve is according to the following 
equation and the representation of it is shown in Figure 62 (pink area). 










Figure 61. The first moment of the data; the plot of concentration*time vs. time. The data are fitted as 
shown by red solid line. 
 
Figure 62. The AUMC extrapolated to infinity using λ. The pink area represents the total area under 
the curve (𝑨𝑼𝑴𝑪𝟎−∞). 
Table 9 summarizes the pharmacokinetic parameters calculated. 
Table 9. Average pharmacokinetics parameters calculated for each group 
PK Parameters 64Cu@Au GNPs (3X) 64Cu@Au GNPs (5X) 
AUC0–∞ (CPM.h/μl) 5,351.6 5,334.9 
AUMC0–∞ (CPM.h2/μl) 209,221 284,577 
Cmax (CPM/ μl) 324.2 204.8 
MRT (h) 39.1 53.3 
Cl (μl/h) 1,862.3 1,868.1 
Vss (μl) 72,798.9 99,647.1 
Kel’ (1/h) 0.03 0.02 
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t1/2 (h) 23.1 34.6 
 
Based on the result provided above, the clearance rate of different concentrations of 64Cu@Au 
GNPs are similar with a good approximation (~ 1.9 ml/h). The mean volume of distribution at 
steady state, Vss was higher with the higher concentration of the particles (~99.7 ml) than the 3X 
concentration (~72.8 ml). The half-life of 64Cu@Au GNPs were also calculated to be ~23 and 35 h 
for 3X and 5X concentrations, respectively. As expected, the clearance rate of 64Cu@Au GNPs is 
comparable to the one of 13 nm-sized PEG-coated GNPs [141], 64Cu@CuS NPs [164], and solid 





















CHAPTER XII  
CONCLUSION OF PART TWO 
To conclude the second part of this work, we developed and characterized non-radioactive Cu@Au 
GNPs confirmed by UV-vis spectrophotometer, TEM, TEM/EDS, XPS and ICP. Then we 
functionalized our hybrid GNPs were with varying amounts of cMBP to target c-Met receptor that 
is expressed on A549 human lung cancer cells. The result of 1 h and 4 h incubation with 
functionalized GNPs indicated that no uptake was taken place. In the next step, we radiolabeled the 
GNPs with 64Cu to produce 64Cu@Au GNPs. Targeting the cells with radiolabeled GNPs did not 
show any cell uptake either. The toxicity of Cu@Au GNPs in A549 cells was studies and the IC50 
of our hybrid Cu@Au GNPs was found to be 807.2 ± 0.05 μg/ml.  This result together with the 
result obtained from biodistribution studies in mice and pharmacokinetics studies in rats confirmed 
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